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Abstract 
Cortical demyelination is a key pathological feature of multiple sclerosis (MS) and 
clinically linked to cognitive deficits and disability progression. Extensive band-like subpial 
demyelination is even a specific feature of the disease. However, the immunological 
mechanisms driving cortical demyelination have not yet been defined due to a lack of 
cortical pathology in the classical experimental models of MS. 
To elucidate the immunopathogenesis of cortical demyelination, we developed a novel 
mouse model with subpial and perivascular cortical MS-like lesions. We demonstrate that in 
addition to a pathogenic anti-myelin antibody response, perivascular cortical demyelination 
is primarily dependent on activated encephalitogenic T cells, natural killer (NK) cells and 
CCR2+ inflammatory monocytes. In contrast, subpial cortical demyelination occurs 
independently of activated T cells, but requires specific antibodies and a fully functional 
complement cascade. 
To translate the results obtained into a treatment option for MS, we evaluated the 
therapeutic efficacy of a humanized mouse anti-human CCR2 antibody, which efficiently 
depletes CCR2+ monocytes in marmosets with experimental autoimmune encephalomyelitis 
(EAE). Depleting inflammatory monocytes was well tolerated and significantly reduced 
cortical demyelination in marmoset monkeys with EAE. 
Our findings thus delineate a differential involvement of immunological effector 
mechanisms in perivascular and subpial cortical lesion formation, shed light on the exquisite 
vulnerability of subpial cortical tissue in multiple sclerosis and translate into a preclinical 
treatment approach for cortical demyelination. 
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1 INTRODUCTION 
1.1  Multiple Sclerosis 
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central 
nervous system (CNS), affecting mostly young adults. The clinical symptomatology of the 
disease is quite heterogeneous and the etiology is not fully understood yet, but likely 
involves a genetic predisposition in close interaction with environmental factors. 
1.1.1  Clinical subtypes 
MS typically starts in adults between 20 and 45 years of age, but it can also occur in 
children (under 18 years of age). Patients with MS experience a variety of symptoms, and 
the most common are visual problems, fatigue, spasticity, problems with gait and balance 
and the presence of the Uhthoff’s phenomenon (a transient temperature-dependent 
numbness, weakness, or loss of vision due to a defective nerve conduction in demyelinated 
axons) (Davis et al., 2008, Browning et al., 2012). 
In 1996, the US National Multiple Sclerosis Society Advisory Committee on Clinical 
Trials in Multiple Sclerosis defined four standardized clinical subtypes of MS (Lublin and 
Reingold, 1996) according to the clinical course of the disease: relapsing-remitting (RRMS), 
secondary progressive (SPMS), primary progressive (PPMS) and progressive relapsing 
(PRMS). These categories did not include imaging and biological correlates as well as clinical 
aspects of the disease recently identified; therefore, they were re-examined in 2012 by the 
International Advisory Committee on Clinical Trials of MS (Lublin et al., 2014). As a result, 
two major consensual changes in the classification system were suggested: the clinically 
isolated syndrome (CIS) was officially included as an MS descriptor and the PRMS category 
was eliminated. The core descriptions of relapsing and progressive disease were maintained, 
but two modifiers of these core phenotypes were settled: disease activity (defined by clinical 
assessment or CNS imaging) and disease progression (assessment of whether progression of 
disability has occurred over a given time period) (Lublin et al., 2014).  
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The different MS subtypes are defined as follows: 
Clinically isolated syndrome 
CIS is defined as the first clinical presentation of a disease showing characteristics of 
inflammatory demyelination that could be MS, but still does not fulfill the criteria of 
dissemination in time (Miller et al., 2005). Disease activity in CIS patients should be followed 
up and in case of subsequent clinical relapses, or new magnetic resonance imaging (MRI) 
lesions, the clinical course should be classified as RRMS (Lublin et al., 2014). 
Relapsing-remitting MS 
Around 85-90 % of the MS patients are diagnosed with RRMS at the onset of the 
disease. The patients experience episodes of neurological deficits (relapses), followed by 
periods of complete or partial recovery of the symptoms (remission) that can last months to 
years (Compston and Coles, 2002). Typically, women have a higher risk than men of 
developing this form of MS. A relapse can be defined as an episode of neurological 
symptoms, which lasts at least 24 h in the absence of fever and infection and is consistent 
with a demyelinating event in the CNS (Polman et al., 2011). According to the disease 
modifiers recently established, RRMS patients can be sub-classified in RR-active [e.g., 
presence of new gadolinium-enhancing (GdE) lesions in MRI] or RR-not active (patient with a 
relapsing course but not presenting clinical relapses, new GdE lesions or enlarging T2 lesions 
during the assessment period) (Lublin et al., 2014). 
Secondary progressive MS 
50 % of the RRMS patients transition into a secondary progressive phase within 2 
decades (Duffy et al., 2014, Scalfari et al., 2014). Men often experience a more rapid 
progression than women (Koch et al., 2010). SPMS patients present with a slow decline of 
neurological functions and often the ability to walk decreases (Browning et al., 2012). To 
date there are no clear criteria to define the transition point when RRMS converts to SPMS 
(Lublin et al., 2014). 
Primary progressive MS 
PPMS accounts for 10-15 % of the MS cases. In the diagnosed patients, the disease 
continuously evolves from the onset, without phases of remission. Contrary to RRMS, men 
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have a higher risk than women of being affected by PPMS and usually the onset is later in life 
(40 years on average) (Noseworthy et al., 2000, Holland et al., 2011). 
According to the International Advisory Committee on Clinical Trials of MS, PPMS and 
SPMS can also be sub-classified based on activity (active versus non-active) and progression 
(with progression versus without progression) (Lublin et al., 2014). 
1.1.2  Diagnosis 
The diagnosis of MS is based on clinical symptoms, MRI findings and analysis of 
cerebrospinal fluid (CSF). Traditionally, MS was diagnosed following the Poser’s criteria 
(Poser et al., 1983), defined as the occurrence of two or more demyelinating attacks 
involving two or more parts of the CNS. Along with the introduction of modern MRI 
techniques, these criteria were substituted by the McDonald criteria implemented in 2000 
(McDonald et al., 2001), and subsequently revised in 2005 (Polman et al., 2005) and 2010 
(Polman et al., 2011). Accordingly, the presence of hyperintense T2-weighted lesions by MRI, 
disseminated in space (DIS) and time (DIT) are predictive for MS. T2 lesions are typically 
located juxtacortically, periventricularly, in the posterior fossa and in the spinal cord. The 
presence of at least one T2 lesion in at least two of the regions mentioned fulfills the DIS 
criterion. The DIT criterion is satisfied when asymptomatic GdE and non-enhancing lesions 
are simultaneously present in one single MRI scan, or when a new T2 or GdE lesion is 
detected on a follow-up MRI (Polman et al., 2011). Acute lesions show enhancement after 
gadolinium administration on T1-weighted images, indicative of inflammatory infiltration 
and a recent breakdown of the blood brain barrier (BBB) (Filippi et al., 2002). Furthermore, 
the presence of oligoclonal bands (OCBs) in the CSF (found in about 90-95 % of the patients) 
and an intrathecal immunoglobulin G (IgG) synthesis both support the MS diagnosis 
(Compston and Coles, 2002). 
1.1.3  Epidemiology and etiology 
MS affects about 2.5 million people around the world, and its incidence is continuously 
increasing (Milo and Kahana, 2010, Browning et al., 2012, Hemmer et al., 2015). MS usually 
starts in early adulthood with a female: male ratio of 3:1 in Caucasians (Constantinescu et 
al., 2011, Wallin et al., 2012). Studies have shown that the incidence of MS is rising with 
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increasing distance to the equator (Koch-Henriksen and Sorensen, 2010), and people with 
Nordic origin are more often affected (Hauser and Goodwin, 2008). Regions of high risk 
comprise Northern Europe, Israel, Northern USA, Canada, New Zealand, San Marino and 
Cyprus (Kurtzke, 2000, Healthline, 2015). In Germany the actual prevalence of the disease is 
149 patients per 100 000 inhabitants (Healthline, 2015). Regions with low prevalence can be 
found in Asia and South America (Kurtzke, 2000). 
The knowledge collected from epidemiological and family studies in patients with MS 
support a role of genetic risk factors in the disease. Studies revealed that first-degree 
relatives of MS patients have seven times higher chances of developing MS compared with 
others (Compston and Coles, 2002). In this respect, an MS concordance rate of 15-25 % in 
monozygotic twins and of 3-5 % in dizygotic twins has been identified (Mumford et al., 1994, 
Hansen et al., 2005, Ramagopalan et al., 2008). 
Since already three decades, genetic variations in the human leukocyte antigen (HLA) 
alleles have been strongly associated with the MS risk (Jersild et al., 1973). For example, the 
HLA class II alleles DRB1*1501, DRB1*0301, and DRB1*1303 expressed on cells of the innate 
immune system, have been linked to an increased risk of developing MS, whereas the HLA 
class I allele A2 is associated with a lower risk to develop MS (Sawcer et al., 2011). Peptides 
are presented to the T cell receptor of Cluster-of-differentiation 4 positive (CD4+) and 
Cluster-of-differentiation 8 positive (CD8+) T cells in the context of HLA class II and I 
molecules by antigen presenting cells (APC), emphasizing the role of the immune system in 
MS. In addition, genetic variations in interleukin-2 (IL-2) and interleukin-7 (IL-7) receptor α 
chains, have been related to an increased susceptibility for the disease (Compston and Coles, 
2008). Furthermore, genome-wide association studies have identified over 100 single 
nucleotide polymorphisms (SNPs) connected to MS (Sawcer et al., 2011, Beecham et al., 
2013, Farh et al., 2015). Interestingly, most of the SNPs identified occurred in gene loci 
related to T cell differentiation, as well as in genes related to modulation and 
reprogramming of T cell effector functions like secretion of cytokines (Sawcer et al., 2011). 
Despite of the solid evidence supporting the role of a genetic component in the 
etiology of the disease, non-genetic factors, namely viral infections and other environmental 
factors, have been also associated with MS. For example, Epstein-Barr virus (EBV) infection 
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was strongly associated with MS (Haahr and Hollsberg, 2006, Ascherio and Munger, 2007, 
Almohmeed et al., 2013) and it has been proposed that molecular mimicry between viral 
and myelin components may play a role in disease pathogenesis (Lang et al., 2002). 
However, defining a conclusive role of the Eppstein-Barr Virus in MS has been undermined 
by the fact that more than 95 % of the adult population is seropositive for the virus (Ascherio 
and Munger, 2007). 
Studies of migration patterns have shown that a child migrating from a high- to a low-
risk region (or the other way around) takes on the risk level of the new location. However, if 
the migration takes place after puberty, the risk from the region of origin is retained 
(Compston and Coles, 2008). Additionally, smoking might increase the risk for MS 1.5-fold 
and might accelerate the transition from RRMS to SPMS (Hernan et al., 2001, Healy et al., 
2009). A recent study addressing the immunological effects of high-dose vitamin D in healthy 
volunteers, reported that a high serum concentration of vitamin D results in increased IL-10 
production by peripheral blood mononuclear cells and a reduced frequency of Th17 cells 
(Allen et al., 2012), which might explain the benefits reported on reducing the risk of MS 
(Ascherio and Munger, 2007). 
1.1.4  Immunopathogenesis 
It is widely accepted that MS pathogenesis has an important immunological 
component. This view is based on findings from immunological, genetic and 
histopathological studies as well as experiences acquired from clinical trials where different 
immunomodulatory and immunosuppressive treatments have been successfully applied. 
Two main hypotheses on the initiation of MS have been postulated. The most widely 
accepted one claims that the activation of a CNS antigen-specific response takes place in the 
periphery and as a result, an adaptive immune response targeting the CNS is orchestrated. 
The second hypothesis proposes that CNS homeostasis is intrinsically disturbed and that this 
initial event will trigger a subsequent adaptive immune response resulting in inflammatory 
demyelination (Hemmer et al., 2015). 
The sequence of events proposed in the first theory is described as follows: 
autoreactive T cells are primed in peripheral lymphoid organs by dendritic cells (DCs) 
through mechanisms of molecular mimicry, bystander activation or direct cross-reactivity 
INTRODUCTION 
 
6 
 
(Wucherpfennig and Strominger, 1995, Sospedra and Martin, 2005). In the draining lymph 
nodes, B cells can also capture soluble antigens and act as APC for the T cells. B cells 
proliferate and mature into antibody-secreting plasma cells, which can migrate to the bone 
marrow or to inflamed tissues. Under specific conditions, a few of these primed T cells, 
together with some B cells invade the CNS compartment (Henderson et al., 2009, Graber and 
Dhib-Jalbut, 2011). T cell migration is mediated by the upregulation of adhesion molecules 
like the very late antigen-4 (VLA-4) in T helper 1 (Th1) cells, which interacts with its ligand, 
the vascular cell adhesion molecule- 1 (VCAM- 1) on endothelial cells. On the other hand the 
migration of T helper 17 (Th17) cells is thought to be mediated by the interaction between 
the chemokine (CC motif) receptor 6 (CCR6) and the chemokine (CC motif) ligand 20 
(Engelhardt and Ransohoff, 2012). Furthermore, activated T cells secrete metalloproteinase 
like the matrix metalloproteinases-2 and -9 (MMP-2, MMP-9) contributing to the breakdown 
of the BBB (Graber and Dhib-Jalbut, 2011). T cells are re-activated by local APC within the 
CNS, preferentially in the perivascular space, and start to secrete pro-inflammatory 
cytokines like interferon-gamma (IFNγ) and interleukin-17 (IL-17) (Axtell et al., 2010), 
creating an inflammatory environment that alters the homeostasis of oligodendrocytes, 
astrocytes and microglial cells. This results in an increased permeability of the BBB and 
additional inflammatory cells are recruited, including monocytes and plasma cells 
contributing to the perpetuation of the lesions (Vogel et al., 2013). In this regard, several 
studies report the presence of monocytes degrading myelin products (Breij et al., 2008, 
Lucchinetti et al., 2011), and plasma cells in the lesions, which potentially could produce 
antibodies targeting myelin sheaths and glial cells (Buc, 2013, Hemmer et al., 2015). 
Regarding the second, alternative hypothesis, resident CNS microglia are activated in 
response to an initiating event, leading to the subsequent amplification of an immune 
response involving a secondary recruitment of innate and adaptive immune cells (Henderson 
et al., 2009). This hypothesis is based on observations made in some lesions or in the normal 
appearing white matter, where oligodendrocyte loss and microglia activation can be 
observed in the absence of lymphocyte infiltrations. It has been proposed that the 
oligodendrocyte loss may be caused by a genetic mutation, a metabolic disturbance or an 
increased vulnerability of these cells, leading to their spontaneous death (Barnett and 
Prineas, 2004). Then, antigens will drain out of the CNS via the CSF, as studies have 
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suggested in mice (Xie et al., 2013), toward deep cervical lymph nodes to induce a secondary 
immune response in the periphery. In most non-CNS tissues, antigens released by local 
tissue damage will be processed and presented by APC in the corresponding draining lymph 
nodes and there, T cells will be primed and subsequently migrate to the target tissue to 
exert their effector functions. Several studies argue against the existence of such an efferent 
route for DCs to leave the CNS (Hatterer et al., 2006, Galea et al., 2007, Ransohoff and 
Engelhardt, 2012). Nevertheless, immune cells bearing DC surface markers have been 
identified in the juxtavascular CNS parenchyma in mice (Prodinger et al., 2011) and their 
migration along the rostral migratory stream (a specialized migratory route reaching the 
main olfactory bulb) to the cervical lymph nodes has been recently described (Mohammad 
et al., 2014). In the cervical lymph nodes, B cells are also capable of recognizing soluble 
antigens and present them to T cells (Yuseff et al., 2013). Finally the activation of antigen-
specific T cells in the draining lymph nodes results in the orchestration of an adaptive 
immune response to target myelin and oligodendrocytes, similar to the one described in the 
previous hypothesis (Hemmer et al., 2015). 
This hypothesis has various detractors, since primary neurodegenerative diseases or 
traumatic insults affecting oligodendrocytes or the myelin sheaths do not regularly lead to a 
destructive activation of the adaptive immune system (Eichler and Van Haren, 2007, Locatelli 
et al., 2012). Furthermore, primary damage to oligodendrocytes is not supported by the 
genetic studies done in patients. Alternatively, the possibility that a persistent infectious 
agent in oligodendrocytes would damage the cells seems unlikely, because in this case, it 
should be expected that most of the damage would be induced by immune infiltrating cells 
trying to clear the pathogen (Hemmer et al., 2015). 
MS has been historically considered a CD4+ T cell driven autoimmune disease, mainly 
based on data derived from experimental autoimmune encephalomyelitis (EAE). However 
CD8+ T cells are observed in active demyelinating lesions, even outnumbering the amount of 
CD4+ T cells (Buc, 2013). Expanded clones of CD8+ T cells are found in the CSF and blood of 
MS patients, persisting even for years (Babbe et al., 2000, Skulina et al., 2004).  
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Also, increased numbers of CD8+ T cells can be observed infiltrating the cortex in MS 
patients at early stages (Lucchinetti et al., 2011) and near demyelinated axons in the CNS 
(Babbe et al., 2000). In addition, acute axonal damage in early MS lesions has been 
correlated with increased numbers of CD8+ T cells within the lesions (Bitsch et al., 2000). 
Regulatory T (Treg) cells seem to be implicated in the pathogenesis of MS as well, since 
a loss of their immunosuppressive functions has been observed in MS patients (Viglietta et 
al., 2004, Haas et al., 2005), possibly contributing to the activation of pathogenic Th1 and 
Th17 cells. In addition, remission phases in RRMS patients are associated with increased 
numbers of Forkhead box P3 (FoxP3)+ Treg cells in the blood (Dalla Libera et al., 2011, 
Peelen et al., 2011). However, few of these cells are found in MS lesions independent of the 
disease activity (Fritzsching et al., 2011), making it difficult to establish their exact 
contribution to lesion formation in the CNS. 
As mentioned above, B cells can contribute to the pathogenesis of MS (Yuseff et al., 
2013), among others by presenting antigens to autoreactive T cells and, upon differentiation 
into plasma cells, by secreting antibodies against myelin structures. In support of this 
hypothesis, deposition of IgG and immunoglobulin M (IgM) on myelin and oligodendroglial 
cells, co-localizing with complement deposition in demyelinated areas, has been shown 
(Storch et al., 1998, Sadaba et al., 2012). Moreover, the presence of OCBs and intrathecal 
IgG synthesis is important for the diagnosis of MS (Sharief and Thompson, 1991). 
Furthermore, the B cell depleting antibody Rituximab significantly reduces the relapse rate 
and disease activity in RRMS patients (Hauser et al., 2008). 
1.1.5  Pathology 
The main pathological characteristics of MS are the presence of multifocal areas in the 
CNS featuring myelin loss, defined as plaques or lesions, accompanied by variable gliosis and 
inflammation and relative axonal preservation (Bruck and Stadelmann, 2005). Lesions 
disseminate through the CNS, but optic nerves, spinal cord, brainstem, cerebellum and 
juxtacortical and periventricular white matter (WM) regions constitute predilection sites 
(Popescu and Lucchinetti, 2012, Popescu et al., 2013).  
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Recent pathological findings highlight the presence of demyelinated lesions also in the 
cortical grey matter (GM) of MS patients (Kidd et al., 1999, Peterson et al., 2001, Bo et al., 
2003a, Bo et al., 2003b, Pirko et al., 2007, Geurts and Barkhof, 2008) already early in the 
disease (Lucchinetti et al., 2011). Cortical grey matter pathology is described in detail in 
section 1.2. 
1.1.5.1  Acute active demyelinating lesions 
Acute active demyelinating lesions are the most frequent lesion type in WM regions in 
RRMS patients underlying the occurrence of clinical attacks in this group (Filippi et al., 2012, 
Popescu and Lucchinetti, 2012, Metz et al., 2014). These plaques contain numerous 
macrophages containing myelin debris, which is considered the pathological signature for 
defining active demyelinating plaques (Bruck et al., 1995). Myelin oligodendrocyte protein 
(MOG), 2´,3´-cyclic nucleotide 3´-phosphodiesterase (CNPase) and myelin associated 
glycoprotein (MAG) are considered “minor”, less abundant, myelin proteins, that can be 
degraded within 1-3 days; therefore, when found in macrophages designate early active 
demyelination. In contrast, if degradation products from “major”, extremely abundant, 
myelin proteins like proteolipid protein (PLP) or myelin basic protein (MBP), which are 
digested more slowly, are identified within macrophages, lesions are classified as late active 
(Popescu et al., 2013). Inactive lesions may still display macrophages but these are not 
immunopositive for any of the myelin proteins mentioned above (Bruck et al., 1995). In 
addition to macrophages/microglia, T cells (CD4+ and CD8+), B-lymphocytes, as well as 
plasma cells invade the CNS parenchyma and perivascular areas (Frischer et al., 2009), 
reinforcing the inflammatory nature of these lesions. Astrocytes proliferate and adopt a 
plump shape, with homogeneous eosinophilic cytoplasm and numerous fibrillary processes 
(Popescu and Lucchinetti, 2012), while oligodendrocyte loss is quite variable (Bruck et al., 
1995). 
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1.1.5.2  Remyelinated lesions 
Remyelinated lesions are characterized by the presence of newly formed, thinner 
myelin sheaths that can be identified as “pale”, mostly sharply delineated areas in LFB-PAS 
histochemistry (Popescu et al., 2013). Frequently, signs of extensive remyelination, such as 
abundant mature oligodendrocytes and MBP- and MOG-positive myelin sheaths, are 
observed within early MS lesions, but remyelination capacity apparently decreases during 
the chronic phase of the disease (Goldschmidt et al., 2009). However, remyelinated plaque 
regions  can be observed in almost half of chronic lesions in MS, mostly at the periphery of 
the lesion (Barkhof et al., 2003, Patrikios et al., 2006). 
1.1.5.3  Axonal and neuronal damage 
Persisting disability in MS is associated with neuronal and axonal degeneration. Axonal 
damage already takes place early in the disease and is most pronounced during active 
demyelination (Trapp et al., 1998, Bitsch et al., 2000, De Stefano et al., 2001, Kuhlmann et 
al., 2002). Axonal damage is evidenced by the presence of axonal swellings and 
accumulation of amyloid-β precursor protein (APP) (Bjartmar et al., 2003). Axonal pathology 
contributes to the disability observed during the relapses of the patients and correlates with 
the extent of inflammatory infiltration in active lesions (Bitsch et al., 2000, Filippi et al., 
2012, Popescu and Lucchinetti, 2012). Neuronal loss in MS has been reported in neocortical 
areas, hippocampus and in demyelinated as well as non-demyelinated cortex (Wegner et al., 
2006, Papadopoulos et al., 2009, Magliozzi et al., 2010, Lucchinetti et al., 2011). It has been 
proposed that neuronal and axonal damage is caused by the secretion of toxic inflammatory 
mediators like reactive oxygen species (ROS), nitric oxide (NO), proteases and cytokines from 
the inflammatory cells, causing mitochondrial dysfunction, oxidative stress and energy 
deficiency (Dutta and Trapp, 2007, Stirling and Stys, 2010, Dutta and Trapp, 2011, Fischer et 
al., 2012). Furthermore, excitotoxic mechanisms might also lead to axonal damage (Pitt et 
al., 2003, Srinivasan et al., 2005). 
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1.1.5.4  Chronic lesions 
Chronic lesion are the most frequent lesion type found in brain autopsies from patients 
with long-standing MS (Stadelmann et al., 2011) and can be classified as chronic active 
lesions (smoldering lesions) or chronic inactive plaques (Popescu et al., 2013). Chronic active 
lesions are well-demarcated areas of demyelination with a hypocellular center surrounded 
by a slowly expanding rim of activated microglia. Few myelin-laden phagocytes can also be 
present at the lesion edge. Additionally, T cells are often found perivascularly located in 
these lesions (Stadelmann et al., 2011). Several studies proposed that smoldering lesions 
might contribute to disease progression in MS (Prineas et al., 2001, Filippi et al., 2012, 
Popescu and Lucchinetti, 2012). On the other hand, chronic inactive lesions are completely 
demyelinated and hypocellular (few macrophages/microglia and lymphocytes), featuring a 
substantial loss of axons (up to 80 %) (Frischer et al., 2009) and oligodendrocytes, as well as 
a dense astrogliosis (Kuhlmann et al., 2008, Popescu and Lucchinetti, 2012). 
1.1.6  Therapies for MS 
So far, there is no cure for MS and the therapies available reduce the relapse rate and 
MRI disease activity (disease-modifying therapies, DMT) or aim at improving symptoms. For 
managing acute relapses in MS, the intravenous (i.v.) administration of high dose 
methylprednisolone is recommended. If this fails, plasma exchange (plasmapheresis) or i.v. 
infusion of Ig (IVIG) should be used (Cortese et al., 2011). DMTs are unfortunately not 
effective in progressive MS (Wingerchuk and Carter, 2014). Up-to-date, several DMT have 
been approved for the long-term treatment of RRMS comprising: interferon-β (IFNβ) (six 
available formulations), glatiramer acetate (GA), teriflunomide, dimethyl fumarate, 
alemtuzumab, natalizumab, fingolimod and mitoxantrone (Gajofatto and Benedetti, 2015). 
Currently, additional studies are carried on to address the potential therapeutic effects of 
new substances like laquinimod, daclizumab and rituximab for MS. 
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1.1.7  Experimental autoimmune encephalomyelitis model 
Several animal models of MS have been developed so far, but the most commonly 
used and also the best understood is the rodent EAE model. EAE can be induced by either 
active immunization with myelin-derived proteins or peptides emulsified in adjuvants 
(Stromnes and Goverman, 2006) or by adoptive transfer of activated myelin-specific CD4+ T 
cells into recipient animals (Ben-Nun et al., 1981, Stromnes and Goverman, 2006). The 
immunization induces the activation of T cells in the periphery (lymph nodes and spleen). 
Subsequently, autoreactive T cells migrate across the BBB into the CNS, where they are 
reactivated by local APC, starting an inflammatory cascade that contributes to the 
recruitment of additional immune cells and leads to tissue injury (Constantinescu et al., 
2011). EAE is most frequently induced in mice, but also rats, marmoset monkeys and other 
species can be used. The disease course is characterized by an ascending paralysis 
manifesting about seven to fourteen days after active EAE immunization or earlier, if 
induced by adoptive transfer protocols. 
EAE targets mostly the spinal cord and sometimes the cerebellum, generating 
inflammation, demyelination and axonal damage, but the pathological features vary 
depending on the animal species, strain, induction method and auto-antigen used. The same 
factors influence the disease course as well (Baxter, 2007, Miller and Karpus, 2007). Thus, 
C57BL/6 mice display a monophasic disease course upon immunization with a variable 
degree of remission, in contrast to SJL/J mice for example, which develop a relapsing-
remitting form of EAE after immunization with PLP139-151 (Gold et al., 2006). 
The generation of the OSE (optico-spinal-EAE) mice that spontaneously develop EAE 
(Krishnamoorthy et al., 2006) has set an important milestone in EAE and MS research. These 
mice were generated by crossbreeding 2D2 mice bearing a T cell receptor (TCR) specifically 
recognizing the MOG35-55 myelin peptide (Bettelli et al., 2003) with Th mice, whose B cell 
receptor (BCR) is also specific for MOG (Litzenburger et al., 1998). OSE mice develop EAE 
spontaneously with an incidence of around 50 % and demyelinating lesions can be found in 
spinal cord as well as optic nerves (Krishnamoorthy et al., 2006). 
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1.2  Grey matter pathology in multiple sclerosis 
For many decades, MS was considered a predominant WM nosological entity, since 
disseminated focal demyelinated lesions constitute a classical hallmark of the disease. 
Nevertheless, early studies already reported grey matter (GM) demyelinated lesions (Sander, 
1898, Dawson, 1916, Lumsden, 1970). It was not until 1962, that post-mortem tissue 
research started to pay more attention to GM pathology in MS. In this early date, a pioneer 
study of post-mortem material from 22 MS patients, reported the occurrence of 
macroscopically visible demyelinated lesions in the cortical GM in 26 % of the cases 
(Brownell and Hughes, 1962). Yet, the lack of specific immunohistochemical techniques at 
that time suggested that this number represented an underestimation of the real prevalence 
of GM lesions (Engelhardt and Ransohoff, 2012, Calabrese et al., 2015). In the beginning of 
the 21st century, the improvement of histopathological methods for staining myelin (Kidd et 
al., 1999, Peterson et al., 2001, Bo et al., 2003b) facilitated the detection of GM 
abnormalities in MS. 
Nowadays, the cortex is recognized as one of the preferential locations of 
demyelination in MS (Kidd et al., 1999, Peterson et al., 2001, Bo et al., 2003b, Kutzelnigg et 
al., 2005, Vercellino et al., 2005, Gilmore et al., 2009). Cortical lesions are predominantly 
located in the insular cortex, the frontobasal cortex, the temporobasal cortex and the gyrus 
cinguli (Kutzelnigg and Lassmann, 2006), although hippocampus and cerebellum can be also 
affected (Geurts et al., 2007). In addition, it has been demonstrated that cortical lesions 
occur independently of WM or deep GM pathology (Bo et al., 2003b, Kutzelnigg et al., 2005, 
Vercellino et al., 2005, Bo et al., 2007). Moreover, cortical demyelination has been 
associated with cognitive impairment of the patients (Calabrese et al., 2009, Roosendaal et 
al., 2009, Rodriguez et al., 2014) and has been related to the occurrence of epileptic seizures 
in MS (Calabrese et al., 2008). 
Cortical demyelination has been reported to be a restricted feature of late-stage MS 
(Bo et al., 2003b, Kutzelnigg et al., 2005). Cortical demyelination was found in almost 95 % of 
post-mortem brains from chronic MS patients (Bo et al., 2003b, Kutzelnigg et al., 2005, 
Albert et al., 2007). Around 40 % of the patients in the progressive phase of the disease also 
displayed large areas of cerebellar demyelinated cortex, which may be a correlate of 
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cerebellar dysfunction in MS (Gilmore et al., 2009). Interestingly, a recent study in biopsy 
material from 138 early MS patients described the presence of extensive cortical lesions in 
38 % of the samples analyzed (Lucchinetti et al., 2011). 
1.2.1  Classification of cortical lesions in multiple sclerosis 
Cortical lesions are classified into three types depending on their localization within 
the cortex. Type 1 lesions (leukocortical), involve both GM and WM and the GM-WM 
junction, while the superficial cortical layers are spared. Type 2 lesions are purely 
intracortical, usually small-sized and located mostly perivascularly around inflamed vessels, 
sparing superficial cortex and adjacent WM. Type 3 lesions (subpial), extend from the pial 
surface of the brain into the deeper cortical layers, sometimes involving several gyri 
(Peterson et al., 2001, Bo et al., 2003a, Calabrese et al., 2010). Subpial lesions are the most 
common type of lesions found in MS autopsies of chronic patients, sometimes covering up 
to 70 % of the cortical area (Kidd et al., 1999, Bo et al., 2003b, Kutzelnigg et al., 2005) and 
are considered a specific feature of the disease (Kidd et al., 1999). 
Cortical demyelinated lesions in early MS 
Early cortical lesions display myelin-laden macrophages, a typical hallmark of active 
demyelination (Lucchinetti et al., 2011, Popescu et al., 2011, Fischer et al., 2013). 
Inflammatory infiltrates located around vessels and also in the parenchyma have been 
observed in these early lesions, composed mostly of macrophages, T cells and few B cells 
and plasma cells (Lucchinetti et al., 2011, Popescu et al., 2011) conferring inflammatory 
features to the lesions. Furthermore, a wealth of inflammatory (adaptive) genes have been 
found upregulated in early cortical lesions in MS, suggesting that the neuronal loss, as well 
as the damage to oligodendrocytes and axons observed in early MS, is not due to a primary 
neurodegenerative process, but rather a result of the inflammation (Fischer et al., 2013). 
The presence of diffuse meningeal inflammation in early MS has been correlated to 
the occurrence of cortical demyelination (Lucchinetti et al., 2011). This observation has led 
to the hypothesis that the secretion of pro-inflammatory cytokines in the subarachnoid 
space (SAS) may be an important driver of cortical pathology not only at this early stage, but 
also in the progressive phase of the disease (Magliozzi et al., 2007, Choi et al., 2012). 
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Cortical demyelinated lesions in chronic MS 
Chronic cortical lesions in MS are characterized by well-demarcated areas of 
demyelination, accompanied by some axonal reduction and decrease of oligodendrocytes 
(Peterson et al., 2001, Albert et al., 2007, Rodriguez et al., 2014). Cortical lesions in 
progressive MS do not exhibit breakdown of the BBB, in contrast to early cortical lesions 
(Popescu et al., 2013). Furthermore, less inflammatory infiltrates and complement 
deposition compared to early WM lesions was observed in such lesions (Peterson et al., 
2001). The presence of meningeal infiltrates formed by T cells, B cells and macrophages 
associated to subpial demyelinated areas has been documented in cortical chronic lesions as 
well (Magliozzi et al., 2007, Howell et al., 2011, Choi et al., 2012), correlating with the 
activation of microglia and the extent of demyelination and neurodegeneration in those 
regions. In addition, meningeal infiltrates consisting of B cell accumulations have been 
described in SPMS, located in the deep cortical sulci and topographically associated to 
subpial lesions (Howell et al., 2011). 
1.2.2  Neuronal damage in cortical lesions 
So far, the relationship of local GM demyelination to neurodegeneration is not clear. 
Some studies reported the presence of neuronal damage and neuronal loss in cortical 
demyelinated lesions, but no differences when comparing NAGM and control cortex 
(Peterson et al., 2001, Wegner et al., 2006). Thus, substantial glial (-36 %) and neuronal loss 
(-10 %), as well as loss of synapses (47 %) was detected in leukocortical lesions, while in 
NAGM the only sign of neuronal damage was the presence of neurons with rounded shapes, 
indicative of axonal and/or dendrite loss (Wegner et al., 2006). In contrast to these findings, 
another study reported a significant loss of neurons (up to 65 % in upper subpial 
demyelinated layers) in both cortical demyelinated lesions and NAGM from SPMS patients, 
when compared with controls (Magliozzi et al., 2010). More recently, another group 
informed the presence of significant neuronal loss (-25 %), neuronal atrophy and axonal loss 
(-31 %) in subpial lesions and NAGM when compared with control samples, but no 
differences were seen if the comparison was done within MS samples (Klaver et al., 2015), 
suggesting that neuronal damage might be largely independent of the demyelination in the 
cortex. 
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1.2.3  MR-imaging of cortical demyelination and clinical correlates 
One of the reasons why cortical demyelination has not been in the focus for several 
decades has to do with the very limited sensitivity of conventional MRI techniques to detect 
these lesions (Geurts et al., 2005a). This also impedes the establishment of good clinical 
correlates of cortical lesions. T1-weighted and T2-weighted standard MRI can detect 
predominantly juxtacortical lesions located at the interface between cortex and WM, but 
subpial lesions, which are the most abundant in cortical demyelination, are the most difficult 
to visualize (Stadelmann et al., 2008). These difficulties partially arise from the intrinsic 
characteristics of cortical demyelinated lesions: low inflammatory load, less BBB damage and 
low myelin density in upper cortical layers. Partial volume effects due to the proximity of 
cortical lesions to the CSF contributes as well (Stadelmann et al., 2008). Imaging methods 
have further evolved, improving the detection of cortical lesions (Boggild et al., 1996, Filippi 
et al., 1996), ranging from the 2-D fast fluid-attenuated inversion recovery (FLAIR) MRI, to 
the 3-D double inversion recovery (DIR) sequences (Geurts et al., 2005b, Pouwels et al., 
2006). However, DIR still misses 80 % of pathologically confirmed, mostly subpial, cortical 
lesions (Seewann et al., 2011, Seewann et al., 2012). 
GM lesion load has been correlated with clinical disability in all MS phenotypes 
(Calabrese et al., 2007, Calabrese et al., 2009, Nelson et al., 2011, Calabrese et al., 2012). For 
example, the size of the cortical lesions, but not the specific location in the cortex, may 
better explain the correlation found with cognitive impairment (Nelson et al., 2011). 
Furthermore, higher lesion loads correlate with higher EDSS, and patients with clinical 
progression have the highest rate of cortical lesion accumulation (Calabrese et al., 2012). 
Nevertheless, the imaging methods available need to be improved to achieve more 
reliability and a better understanding of how cortical demyelination relates to the disease 
process and to clinical disability in MS. 
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1.3 Experimental models of cortical demyelination 
Along with the growing interest in MS cortical pathology, several experimental models 
of cortical demyelination have been reported in rodents and non-human primates during the 
last decade, but still the pathological mechanism leading to the formation of the lesions are 
only poorly understood. 
It has been shown that common marmoset monkeys immunized with recombinant 
MOG protein (rMOG) develop - in addition to WM lesions - cortical demyelinated lesions 
reflecting all the subtypes described in MS (subpial, perivascular and leukocortical lesions) 
(Pomeroy et al., 2005, Merkler et al., 2006c, Kramann et al., 2015). Inflammatory infiltrates 
composed of numerous activated macrophages/microglia and T cells in a lesser extent, as 
well as few perivascular B cells (Merkler et al., 2006c) have been identified in the lesions. A 
more recent study, reported the presence of higher numbers of T cells and plasma cells in 
the meninges overlying subpial cortical demyelinated regions in the marmoset-EAE model 
when compared to normal appearing cortex (Kramann et al., 2015). These findings suggest 
that local meningeal infiltrates might relate to subpial pathology. Furthermore, cortical 
lesions in the marmoset revealed Ig leakage and complement C9 deposition restricted to 
perivascular vessels located intracortically (Merkler et al., 2006a, Merkler et al., 2006c), 
suggesting a possible contribution of pathogenic antibodies and complement to the lesion 
pathogenesis. 
Cortical demyelination has been also observed in congenic Lewis rats sharing certain 
major histocompatibility complex (MHC) I and II alleles and immunized with rMOG (Storch et 
al., 2006), demonstrating that the presence of cortical lesions is controlled by MHC genes. 
The most frequent type of lesions observed in this model corresponded to the subpial 
classification. In addition, deposition of Ig and complement on myelin sheaths was observed 
in subpial-demyelinated areas, accompanied by macrophage infiltration during the early 
stage of lesion formation (Storch et al., 2006). Moreover, cortical demyelination have been 
induced in sub-clinically MOG-immunized rats following a cortical targeted lesion approach 
for the local application of pro-inflammatory cytokines in the cortex (Merkler et al., 2006b, 
Rodriguez et al., 2014). Furthermore, a recent study reported the generation of cortical 
demyelinated lesions in rats by administration of inflammatory cytokines in the SAS, at the 
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sagittal sulcus (Gardner et al., 2013). In these models, inflammation resolves quickly, 
followed by a successful remyelination of the lesions. This was true even when the animals 
were subjected to repeated episodes of inflammatory demyelination (Rodriguez et al., 
2014). Similar to observations made in the marmoset-EAE model (Kramann et al., 2015), 
Gardner and colleagues reported the presence of T and B cells accumulating in the meninges 
of rats displaying extensive subpial demyelinated areas (Gardner et al., 2013). 
Only few studies have reported the presence of cortical demyelination in murine 
models. For example, C57BL/6 mice fed with cuprizone exhibited prominent cortical 
demyelination (Skripuletz et al., 2008) in addition to the demyelination of the corpus 
callosum typically observed in this model (Matsushima and Morell, 2001, Torkildsen et al., 
2008). These mice showed cortical demyelination after 6 weeks of cuprizone feeding, 
followed by a time-dependent remyelination after cuprizone was removed from the diet 
(Skripuletz et al., 2008). Furthermore, the authors demonstrated that cuprizone-induced 
cortical demyelination in the mice is strain-dependent, since BALB/cJ mice, exhibited 
significantly less cortical demyelination when fed with cuprizone. However, it is difficult to 
made inferences regarding the pathogenic mechanisms leading to cortical demyelination in 
MS out of this model, because there is neither an involvement of the adaptive immune 
system nor a disruption of the BBB (McMahon et al., 2001, Praet et al., 2014), like it is the 
case in MS. Furthermore, in situ analysis of myelin in the classic chronic EAE model in 
C57BL/6 mice immunized with MOG35-55 revealed a mild loss of myelin in the cerebral cortex 
(Girolamo et al., 2011), making it hard to establish any resemblance to cortical demyelinated 
lesions in MS. 
In general, these experimental models of cortical demyelination rely on the presence 
of demyelinating antibodies against MOG and the local opening of the cortical BBB, 
supporting the hypothesis of a role for meningeal inflammation and complement mediated 
damage in cortical demyelination in MS. However, a more detailed description of the 
mechanisms regulating the formation of the different types of cortical lesions is still missing. 
Therefore, the establishment of a new mouse model of cortical demyelination in transgenic 
animals allowing the realization of functional studies is required. 
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1.4  Aims of the study 
Cortical demyelination is a pathological hallmark of MS. So far, animal models with 
cortical demyelination have been established in marmosets and rats. 
The aims of the present study are listed below: 
1. To establish a mouse model of cortical demyelination on a C57BL/6 
background. 
2. To characterize the immunological mechanisms of cortical lesion formation.  
3. To evaluate, if the identified pathomechanisms can serve as a target for a novel 
treatment approach against cortical demyelination. 
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2 MATERIALS AND METHODS  
2.1  Materials 
2.1.1  Reagents 
Table 1: Reagents 
Reagent Supplier 
3,3´-diaminobenzidine (DAB) Sigma Aldrich, St. Louis, MO, USA 
Acetic acid Sigma Aldrich, St. Louis, MO, USA 
Agarose StarLab GmbH, Hamburg, Germany 
Albumin, fluorescein isothiocyanate conjugate Sigma Aldrich, St. Louis, MO, USA 
Aquatex medium Merck Millipore, Darmstadt, Germany 
BD FACSTM Lysing solution, 10x BD Biosciences, Franklin Lakes, NJ, USA 
BD Pharm LyseTM , 10x BD Biosciences, Franklin Lakes, NJ, USA 
Betaine Q Sigma Aldrich, St. Louis, MO, USA 
Boric acid Merck Millipore, Darmstadt, Germany 
DePex medium VWR International, Darmstadt, Germany 
(DAPI) Diamidino-2-phenylindole, 1 mg/ml Thermo Scientific, Waltham, MA, USA 
dimethyl sulfoxide Sigma Aldrich, St. Louis, MO, USA 
dNTP (desoxynucleoside triphosphate) mix Thermo Scientific, Waltham, MA, USA 
EDTA (ethylenediamine tetraacetic acid disodium 
salt dihydrate) 
Carl Roth, Karlsruhe, Germany 
Ethanol, 100 % Merck Millipore, Darmstadt, Germany 
Ethidium bromide Sigma Aldrich, St. Louis, MO, USA 
ExtrAvidin-Peroxidase, buffered aqueous solution Sigma Aldrich, St. Louis, MO, USA 
Fast Blue BB Salt hemi (zinc chloride) salt Sigma Aldrich, St. Louis, MO, USA 
FCS (fetal calf serum) Sigma Aldrich, St. Louis, MO, USA 
Fluorescence mounting medium Dako, Deutschland GmbH, Hamburg 
FoxP3 Fixation/Permeabilization Concentrate eBioscience, San Diego, CA, USA 
FoxP3 Fixation/Permeabilization Diluent eBioscience, San Diego, CA, USA 
FoxP3 Permeabilization buffer, 10X eBioscience, San Diego, CA, USA 
GeneRulerTM, 100 bp DNA ladder Plus Thermo Scientific, Waltham, MA, USA 
Go-Taq® DNA polymerase buffer, 10x Promega, Madison, WI, USA 
Go-Taq® DNA polymerase buffer, 5x Promega, Madison, WI, USA 
HCl (hydrochloric acid) Merck Millipore, Darmstadt, Germany 
HEPES (4-(2-hydroxyethyl)-1- Sigma Aldrich, St. Louis, MO, USA 
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Reagent Supplier 
piperazineethanesulfonic acid) buffer, 1 M 
Isopentane Sigma-Aldrich, St. Louis, MO, USA 
Isopropyl alcohol Merck Millipore, Darmstadt, Germany 
Ketamine, 10 % Medistar®, Ascheberg, Germany 
L-glutamine, 200 mM Sigma Aldrich, St. Louis, MO, USA 
Lithium carbonate Sigma Aldrich, St. Louis, MO, USA 
Luxol fast blue (LFB) VWR International LLC, Radnor, PA, USA 
Mannide monooleate Sigma Aldrich, St. Louis, MO, USA 
Mayer´s hemalaum solution Merck Millipore, Darmstadt, Germany 
MEM (minimum essential medium) non-essential 
amino-acids, 100x 
Sigma Aldrich, St. Louis, MO, USA 
MgCl2 (magnesium chloride) Promega, Wisconsin, USA 
N,N-Dimethylformamide Sigma Aldrich, St. Louis, MO, USA 
NaCl (sodium chloride) Carl Roth, Karlsruhe, Germany 
NaCl (sodium Chloride), 0.9 % solution, sterile B. Braun Melsungen AG, Germany 
Naphtol-AS-MX phosphate, disodium salt Sigma Aldrich, St. Louis, MO, USA 
OCT medium Tissue-Tek, Sakura Finetek, USA 
Paraffin oil Carl Roth, Karlsruhe, Germany 
Paraformaldehyde (PFA) Merck Millipore, Darmstadt, Germany 
PBS (phosphate buffered salt solution), sterile Sigma Aldrich, St. Louis, MO, USA 
Penicillin, 10 000 units/streptomycin, 10 mg/ml Sigma Aldrich, St. Louis, MO, USA 
Percoll GE Healthcare Life Science, Germany 
Periodic acid Sigma Aldrich, St. Louis, MO, USA 
Perm/WashTM buffer, 10x BD Biosciences, Franklin Lakes, NJ, USA 
QIAzol Lysis Reagent Qiagen, Maryland, MD, USA 
RPMI-1640 (Roswell Park Memorial Institute-1640) Sigma Aldrich, St. Louis, MO, USA 
Schiff´s reagent Sigma Aldrich, St. Louis, MO, USA 
SDS (sodium dodecyl sulfate) Sigma Aldrich, St. Louis, MO, USA 
Sodium carboxymethyl cellulose (CMC) Sigma-Aldrich, St. Louis, MO, USA 
Sodium pyruvate, 100 mM Sigma Aldrich, St. Louis, MO, USA 
Tris (tris(hydroxymethyl)aminomethane) Carl Roth, Karlsruhe, Germany 
Trypan blue Sigma Aldrich, St. Louis, MO, USA 
Xylazine solution, 20 mg/ml Ecuphar, Oostkamp, Belgium 
Xylene Chemsolute, Th. Geyer GmbH & Co. KG, 
Renningen, Germany 
β-mercaptoethanol Sigma Aldrich, St. Louis, MO, USA 
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2.1.2  Composition of solutions, buffers and cell culture media 
Table 2: Solutions, buffers and cell culture media composition 
Solution Composition 
3,3’ DAB solution Stock Solution: 1 g DAB, 40 ml PBS 
Working solution: 1 ml stock solution, 49 ml 
PBS, 20 µl 30 % H2O2 
CFA (Complete Freund´s Adjuvant) 85 % Paraffin oil, 15 % Mannide monooleate, 
6.7 mg/ml Mycobacterium tuberculosis H37RA 
Chloral hydrate 14 % anesthesia 100 ml bidistilled water, 14 g Chloral hydrate 
DMEM (High Glucose (4.5 g/l), w/ L-Glutamine, 
sodium pyruvate 
Gibco, Life Technologies GmbH, Darmstadt, 
Germany 
FACS (fluorescence-activated cell sorting) buffer PBS, sterile, 2 % FCS 
Fast Blue Solution Bidistilled water, Tris-HCl buffer pH 8.2, 
Naphtol-AS-MX phosphate, N,N-
Dimethylformamide, Levamisol, Fast Blue BB 
salt 
HCl buffer 1 ml 2M HCl, 500 ml bidistilled water, pH 2.5 
IFA (Incomplete Freund´s Adjuvant) 85 % Paraffin oil, 15 % mannide monooleate 
Ketamine/Xylazine anesthesia  NaCl, 0.9 %, sterile, 12 % Ketamine, 10 % 
Xylazine 
Luxol Fast Blue (LFB) solution 1 g LFB, 1000 ml 96 % Ethanol, 5 ml 10 % 
Acetic acid 
Paraformaldehyde (PFA), 4 % 4 g PFA, 100 ml PBS, pH 7.4 
RPMIcomplete RPMI-1640, 10 % FCS, 1 mM sodium pyruvate, 
1x non-essential amino acids, 13 mM HEPES 
buffer, 50 µM β-mercaptoethanol, 100 units 
penicillin, 0.1 mg/ml streptomycin, 2 mM L-
glutamine 
Tail Lysis Buffer Bidistilled water, 0.1 M Tris-HCl pH 8.5, 5 mM 
EDTA, 200 mM NaCl, 0.2 % SDS, pH 8.5 
TBE (Tris/Borate/EDTA) buffer Bidistilled water, 90 mM Tris, 90 mM Boric 
acid, 2 mM EDTA 
Tris-buffered saline (TBS) 1X 50 mM Tris-Cl pH 7.5, 150 mM NaCl 
Tris-EDTA buffer Bidistilled water, 10 mM Tris Base, 1mM EDTA, 
pH 9.0 
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2.1.3  Antibodies for intracerebral injection and bacteria derived products 
Table 3: Antibodies for intracerebral and intravenous injection and bacteria-derived 
products 
Organism Supplier 
8-18C5 hybridoma Prof. Dr. Christopher Linington, University of 
Glasgow, UK 
Z2 hybridoma Prof. Dr. Christopher Linington, University of 
Glasgow, UK 
Mycobacterium butyricum desiccated, non-viable DIFCO, Detroit, MI, USA 
Mycobacterium tuberculosis H37RA, non-viable DIFCO, Detroit, MI, USA 
 
2.1.4  Proteins, cytokines and dyes 
Table 4: Proteins and enzymes 
Proteins and enzymes Supplier 
Collagenase D Roche, Basel, Switzerland 
DNAse I Roche, Basel, Switzerland 
Go-Taq® DNA polymerase Promega, Madison, WI, USA 
MOG35-55 Institute of Medical Immunology, University Medical Center Charité, 
Berlin, Germany 
OVA323-339, chicken InvivoGen, San Diego, CA, USA 
Proteinase K Sigma Aldrich, St. Louis, MO, USA 
PTX (pertussis toxin) List Biological Laboratories, Campbell, CA, USA 
RedTaq® DNA polymerase Sigma Aldrich, St. Louis, MO, USA 
rMOG1-125 His-tag purified at the Institute of Neuropathology, University 
Medical Center, Göttingen, Germany 
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Table 5: Cytokines and dyes 
Cytokines and dyes Supplier 
FITC-Albumin Sigma Aldrich, St. Louis, MO, USA 
IFNγ, mouse, recombinant R&D Systems, Minneapolis, MN, USA 
IL-12, mouse, recombinant R&D Systems, Minneapolis, MN, USA 
IL-2, mouse, recombinant R&D Systems, Minneapolis, MN, USA 
Monastral blue Sigma Aldrich, St. Louis, MO, USA 
TNFα, mouse, recombinant R&D Systems, Minneapolis, MN, USA 
 
Table 6: Monoclonal antibodies for flow cytometry 
Specificity Clone Fluorochrome Dilution Supplier 
Anti-B220 RA3-6B2 PerCP 1:200 BD Biosciences, Franklin Lakes NJ, USA 
Anti-CCR2 475301 APC 1:10 R&D Systems, Minneapolis, MN, USA 
Anti-CD11b M1/70 PE-Cy7 1:200 BioLegend, San Diego, CA, USA 
Anti-CD11c N418 PE 1:200 BioLegend, San Diego, CA, USA 
Anti-CD16/32 93 - 1:100 BioLegend, San Diego, CA, USA 
Anti-CD19 eBio1D3 FITC 1:200 eBioscience, San Diego, CA, USA 
Anti-CD25 PC61.5 APC 1:200 eBioscience, San Diego, CA, USA 
Anti-CD3 145-2C11 FITC 1:200 BioLegend, San Diego, CA, USA 
Anti-CD4 RM4-5 PerCP 1:200 BioLegend, San Diego, CA, USA 
Anti-CD45 30-F11 APC-Cy 1:200 BioLegend, San Diego, CA, USA 
Anti-CD8 53-6.7 PE-Cy7 1:200 BioLegend, San Diego, CA, USA 
Anti-FoxP3 FJK-16S PE 1:100 eBioscience, San Diego, CA, USA 
Anti-Ly6C HK1.4 PE-Cy7 1:200 BioLegend, San Diego, CA, USA 
Anti-Ly6G 1A8 PE 1:500 BioLegend, San Diego, CA, USA 
Anti-NK1.1 PK-136 PE-Cy7 1:500 BioLegend, San Diego, CA, USA 
Anti-Nkp46 29A1.4 PerCP 1:200 BioLegend, San Diego, CA, USA 
Anti-γδ TCR eBioGL3 APC 1:200 eBioscience, San Diego, CA, USA 
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2.1.5  Antibodies and inhibitors for depletion and blocking experiments 
Table 7: Antibodies and inhibitors for depletion and blocking experiments 
Name/Specificity Clone Species/Isotype Application Supplier 
AMBA  n/a Mouse/IgG Isotype control 
antibody 
Prof. Dr. Matthias 
Mack, University 
Hospital Regensburg, 
Germany 
Anti-KLH LTF-2 Rat/IgG2b Isotype control 
antibody 
Bio X Cell, West 
Lebanon, NH, USA 
Anti-Ly6G 1A8 Rat/IgG2a PMN depletion Bio X Cell, West 
Lebanon, NH, USA 
Anti-m/h VLA4 
(Cd49d) 
PS/2 Rat/IgG2b Inhibition of leukocyte 
transmigration into the 
CNS 
Bio X Cell, West 
Lebanon, NH, USA 
Anti-NK1.1 PK136 Mouse/IgG2a NK cell depletion Bio X Cell, West 
Lebanon, NH, USA 
BB5.1 BB5.1 Mouse/IgG1 C5 convertase inhibitor Hycult Biotech, 
Plymouth, USA 
DOC-2 Fr-2 DOC-2 Mouse/IgG 1 Depletion of CCR2+ 
monocytes in 
marmosets 
Prof. Dr. Matthias 
Mack, University 
Hospital Regensburg, 
Germany 
Mouse Isotype 
Control 
MOPC-21 Mouse/IgG1 Isotype control 
antibody 
BioLegend, San 
Diego, CA, USA 
RS 504393 n/a n/a Selective CCR2 
antagonist 
R&D Systems, 
Minneapolis, MN, 
USA 
Unknown 2A3 Rat/IgG2a Isotype control 
antibody 
Bio X Cell, West 
Lebanon, NH, USA 
Unknown C1.18.4 Mouse/IgG2a Isotype control 
antibody 
Bio X Cell, West 
Lebanon, NH, USA 
Unknown R35-95 Rat/IgG2a Isotype control 
antibody 
BD Biosciences, NJ, 
USA 
 
Table 8: Antibodies for antigen-independent activation of T-cell proliferation in vitro 
Specificity Clone Supplier 
Anti-CD28 PV-1 Bio X Cell, West Lebanon, NH, USA 
Anti-CD3 145-2C11 Bio X Cell, West Lebanon, NH, USA 
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2.1.6  Antibodies for histology and immunohistochemistry 
Table 9: Primary antibodies used in paraffin-embedded and frozen tissue 
Antigen Species Dilution Antigen retrieval/Buffer Catalog No. Supplier 
APP Mouse 1:2000 Microwave/Citrate 
buffer 10 mM, pH 6 
MAB348 Chemicon, Temecula, CA, 
USA 
CCR2 Rabbit 1:100 Microwave/Tris-EDTA 
Buffer, 10 mM, pH 9 
ab32144 Abcam, Cambridge, UK 
CD107b 
(Mac-3) 
Rat 1:200 Microwave/Citrate 
buffer 10 mM, pH 6 
553322 BD Bioscience, Franklin 
Lakes NJ, USA 
CD14 Mouse 1:10 Microwave/Tris-EDTA 
Buffer, 10 mM, pH 9 
NCL-CD14-
223 
Leica Biosystems 
Newcastle Ltd., UK 
CD3 Rabbit 1:150 Microwave/Citrate 
buffer 10 mM, pH 6 
C1597C01 DCS, Hamburg, Germany 
CD3 Rabbit 1:50 Microwave/HCl 2 mM, 
pH 2.5 
A0452 Dako, Hamburg, 
Germany 
FITC Rabbit 1:50 Microwave/Citrate 
buffer 10 mM, pH 6 
P5100 Dako, Hamburg, 
Germany 
GrB Mouse 1:50 Microwave/HCl 2 mM, 
pH 2.5 
M7235 Dako, Hamburg, 
Germany 
KiM1P Mouse 1:5000 Microwave/Citrate 
buffer 10 mM, pH 6 
n/a Provided by the Institute 
of Pathology, University 
of Kiel, Germany 
MBP Rabbit 1:1000 n/a A0623 Dako, Hamburg, 
Germany 
NeuN Mouse 1:200 Microwave/Citrate 
buffer 10 mM, pH 6 
MAB377 Merck Millipore, 
Darmstadt, Germany 
NKp46/NC
R1 
Goat 1:50 Ethanol fixation 1 h, 
Cryosections 
AF225 R&D Systems, 
Minneapolis, MN, USA 
Olig2 Rabbit 1:150 Microwave/Citrate 
buffer 10 mM, pH 6 
Tris-EDTA Buffer, 
10 mM, pH 9 
18953 IBL, Hamburg, Germany 
rMOG Rat 1:1000 Microwave/Citrate 
buffer 10 mM, pH 6 
n/a Purified at the Institute 
of Neuropathology, 
UMG, Germany 
TPPP/p25 Rabbit 1:500 Microwave/Tris-EDTA 
Buffer, 10 mM, pH 9 
92305 Abcam, Cambridge, UK 
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Table 10: Secondary biotinylated antibodies for IHC 
Species/Specificity Dilution Blocking buffer Catalog No. Supplier 
Anti-mouse, 
biotinylated 
1:200 10 % FCS/PBS RPN1001 GE Healthcare Ltd, UK 
Donkey-anti-goat, 
biotinylated 
1:200 10 % FCS/PBS RPN1025 GE Healthcare Ltd, UK 
Donkey-anti-rabbit, 
biotinylated 
1:100 10 % FCS/PBS RPN 1001 GE Healthcare Ltd, UK 
Goat-anti-rabbit-AP 1:50 10 % FCS/TBS D 0487 Dako, Hamburg, Germany 
Goat-anti-rabbit-AP 1:50 10 % FCS/Tris-EDTA 
Buffer, 10 mM, pH 9 
D 0487 Dako, Hamburg, Germany 
Goat-anti-rat 1:500 10 % FCS/PBS AS-2100-16 DCS, Hamburg, Germany 
Rabbit-anti-rat, 
biotinylated 
1:100 10 % FCS/PBS E0468 Dako, Hamburg, Germany 
 
Table 11: Secondary antibodies fluorochrome-conjugated for fluorescent IHC 
Specie/Specificity Dilution Blocking buffer Catalog No. Supplier 
CyTM3-conjugated 
Streptavidin 
1:100 10 % FCS/PBS 016-160-184 Jackson ImmunoResearch Lab, 
PA, USA 
goat-anti-mouse 
CyTM3-conjugated  
1:200 10 % FCS/PBS 115-165-146 Jackson ImmunoResearch Lab, 
PA, USA 
Goat-anti-rabbit 
AlexaFluor® 488 
1:200 10 % FCS/PBS A11034 Molecular Probes, OR, USA 
 
2.1.7  Kits 
Table 12: Kits used 
Kit Supplier 
High Capacity RNA-to-cDNATM Kit Life Technologies, Applied Biosystems, USA 
Naphtol AS-D Chloroacetate (Specific esterase) kit Sigma-Aldrich, St. Louis, MO, USA 
qPCR Core Kit Eurogentec, Germany 
RNeasy Micro Kit Qiagen, Germany 
Tyramide Signal Amplification kit (TSATM Kit 21) Invitrogen, Life Technologies, USA 
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2.1.8  Oligonucleotide primers and FAM labeled primers/probes 
Table 13: Oligonucleotide primers for genotyping of transgenic mice 
Name Sequence (5´-> 3´) (bp) Gene Mouse Line  
8.18C5-antisense GGA GAC TGT GAG AGT GGT GCC T (22) anti-MOG IgH 
(8.18C5) 
Th  
8.18C5-sense TGA GGA CTC TGC CGT CTA TTA CTG T (25) anti-MOG IgH 
(8.18C5) 
Th  
CD59_exon 3 GCT ACC ACT GTT TCC AAC CGG TG (23) Cd59a Th/+ CD59a-/- 
CD59_neomycin GAA CCT GCG TGC AAT CCA TCT TG (23) Cd59a Th/+ CD59a-/- 
CD59a_intron 3 GGT GAC CAA CTG GTG TTA ACA AAG GG 
(26) 
Cd59a Th/+ CD59a-/- 
Ja18-2D2-M GCG GCC GCA ATT CCC AGA GAC ATC CCT 
CC (29) 
Valpha 3.2 TCR 2D2  
mIgH-antisense TGG TGC TCC GCT TAG TCA AA (20) Igh-J  Th  
mIgH-sense ATT GGT CCC TGA CTC AAG AGA TG (23) Igh-J Th  
oIMR0301 CTT CTT AGT CCT TCA GCT GC (20) Il2rg ,gamma chain Rag1-/- γc-/- 
oIMR0302 AGG CTC AGA ACT GCT ATT CC (20) Il2rg ,gamma chain Rag1-/- γc-/- 
oIMR0303 GTA TGG TAG TGT TCT CAC CG (20) Il2rg ,gamma chain Rag1-/- γc-/- 
RAG com reverse CCG GAC AAG TTT TTC ACT GT (20) RAG1 Rag1-/-  
RAG mutant forward TGG ATG TGG AAT GTG TGC GAG (21) RAG1 Rag1-/- 
RAG wt forward GAG GTT CCG CTA CGA CTC TG (20)  RAG1 Rag1-/- 
Va3.2-2D2-M GGG CAA GGC TCA GCC ATG CTC CTG (24) Vα 3.2 TCR 2D2  
WAK 121 TTC CAT TGC TCA GCG GTG CT (20) Ccr2 Th/+ CCR2-/- 
WAK 134 TCA GAG ATG GCC AAG TTG AGC AGA (24) Ccr2 Th/+ CCR2-/- 
WAK 32 GTG AGC CTT GTC ATA AAA CCA GTG (24) Ccr2 Th/+ CCR2-/- 
Oligonucleotide primers for the genotyping of 2D2, Th and Rag1-/- mice were purchased from Eurofins 
Genomics, Germany. For the genotyping of Th/+ CD59a-/-, Th/+ CCR2-/- and Rag1-/- γc-/- mice, additional 
primers were kindly provided by Dr. Benoit Barrette, Max Planck Institute for Experimental Medicine, 
Göttingen, Germany. 
 
Table 14: FAM labeled primers/probes for qRT-PCR 
Name Gene Supplier 
Mm00440502_m1 NOS2/iNOS TaqMan® Gene Expression Assays, Life Technologies, USA 
Mm00441242_m1 CCL2 TaqMan® Gene Expression Assays, Life Technologies, USA 
Mm00443258_m1 TNFα TaqMan® Gene Expression Assays, Life Technologies, USA 
Mm99999915_g1 Gapdh TaqMan® Gene Expression Assays, Life Technologies, USA 
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2.1.9  Consumables 
Table 15: Consumable material 
Consumable Source of supply 
Blaubrand® intraMARK micropipettes, 5 µl Brand GmbH, Wertheim, Germany 
ButterflyTM Winged Infusion Set (25G x ¾”) Hospira UK Ltd, UK 
Cell culture dish, 60 x 15 mm Greiner bio-one, Kremsmuenster, Austria 
Cell strainer (70 µm) BD Biosciences, Franklin Lakes, NJ, USA 
FACS tube, 5 ml BD Biosciences, Franklin Lakes, NJ, USA 
Feather disposable scalpel (No. 11, No. 21) PFMmedical AG, Köln, Germany 
GEM® Scientific Razor Blades  Alpha Biotech Ltd., Glasgow, UK 
Needles (23G, 26G) BD Biosciences, Franklin Lakes, NJ, USA 
NuncTM MaxiSorp® 96 well ELISA plate Thermo Scientific, Waltham, MA, USA 
NuncTM MicrowellTM Plates, 96 well round bottom Thermo Scientific, Waltham, MA, USA 
Syringes (1 ml, 5ml, 10 ml, 20 ml) BD Biosciences, Franklin Lakes, NJ, USA 
Tubes (0.2 ml, 1,5 ml, 2 ml, 15 ml, 50 ml) Sarstedt, Nuembrecht, Germany 
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2.1.10  Technical devices 
Table 16: Technical devices 
Device Supplier 
Centrifuge 5415 R Eppendorf, Hamburg, Germany 
Centrifuge 5810 R Eppendorf, Hamburg, Germany 
Cryostat Leica CM3050 Leica Instruments GmbH, Germany 
FACS CantoTM II BD Biosciences, Franklin Lakes, NJ, USA 
Fluorescence/light microscope, Olympus BX51 Olympus, Germany 
Hera cell 150 incubator Heraeus, Hanau, Germany 
iQ5TM Real Time PCR Detection System Bio-Rad Laboratories, Germany 
Keyence Bio REVO BZ-X710 microscope Keyence, Japan 
Microtome Leica SM2000R Leica Instruments GmbH, Germany 
Neubauer chamber Superior Marienfeld, Lauda-Koenigshofen, Germany 
Ocular morphometric grid, 10x10 Olympus, Japan 
Power Pac 300 Bio-Rad Laboratories, Germany 
Speed vacuum Concentrator 5301 Eppendorf, Hamburg, Germany 
Stereotactic device Stoelting Co., Germany 
T3 Thermocycler Biometra, Germany 
Thermo mixer comfort  Eppendorf, Hamburg, Germany 
UV transluminator Vilber Lourmat, Eberhardzell, Germany 
2.1.11  Software 
Table 17: Software 
Software Application Supplier 
BD FACSDiva 6.1.2 Data acquisition flow cytometry BD Biosciences, Franklin Lakes, NJ, USA 
BZ-II analyzer Photomerge of high resolution 
images 
Keyence, Japan 
CellSens Dimension v.1.7.1 
DP71 
Image acquisition Olympus, Germany 
FlowJo 7.6.1  Data analysis flow cytometry Tree Star Inc., Ashland, OR, USA 
GraphPad Prism 5.01 Statistical analysis GraphPad software Inc., La Jolla, CA, 
USA 
Image J v.1.46r Analysis of digital images NIH, USA 
LabVIEWTM-based software  Record of running wheel 
performance 
National Instruments Corp., Germany 
PSRemote 1.6.5 Gel documentation Breeze System Limited, Camberley, UK 
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2.2  Human tissue samples 
In the present study, brain tissue samples including cerebral cortex from eight patients 
diagnosed with inflammatory demyelination compatible with MS, were available for analysis 
(see Table 18). Biopsies were performed for diagnostic purposes to exclude the differential 
diagnoses of lymphoma, tumor or infection. The study was approved by the local ethics 
committee (Nr. 14/5/03). 
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Table 18: Clinical findings of MS biopsy cases used in the present study 
MS case Age/Sex Disease duration (month) 
Disease 
course Presenting symptom(s) Brain MRI 
Index 
lesion OCBs 
1 45/F 6 CIS Slight ataxia, unsteady gait Multiple intracerebral WM lesions in subcortical, cortical and periventricular areas 
Right 
frontal N/A 
2 48/F 11 RRMS Blurred vision of right eye Multiple intracerebral WM lesions, partly cortical and subcortical 
Left 
parietal + 
3 34/F 3 RRMS Blurred vision of left eye 
Multiple intracerebral WM lesions, 
juxtacortical and brain stem, partly contrast-
enhancing 
Right 
temporal - 
4 39/F 0.3 CIS Minor weakness of left hand Single lesion frontal right Right frontal + 
5 26/F 2 CIS 
Minor weakness of left hand, 
symptomatic epilepsy with focal 
motor seizures 
Several intracerebral WM lesions: three 
subcortical lesions (≤ 3 cm diameter), partly 
ring-enhancing; two brain stem lesions 
Right 
frontal + 
6 13/F 116 RRMS 
Weakness of both legs, pre-existing 
symptomatic epilepsy, hand tremor, 
dysarthria 
Several supratentorial lesions, partly contrast-
enhancing 
Left 
frontal - 
7 42/F 2 CIS Vision loss, disturbed balance, depression, beginning dementia 
Multiple subcortical and periventricular WM 
lesions, partly contrast-enhancing 
Left 
frontal N/A 
8 64/M 1 CIS Fatigue, aphasia Three lesions: precentral left, temporal left, frontal right, partly contrast-enhancing 
Left 
temporal N/A 
Legend 
Based on the number of relapses, biopsy cases were either classified as clinically isolated syndrome (CIS) or relapsing-remitting MS (RRMS). CIS patients underwent 
biopsy after the first relapse. OCBs: oligoclonal bands; F: female; M: male; N/A: not available 
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2.3  Animals 
2.3.1  Mouse strains 
The following mouse strains were used for in vivo experiments and/or cell isolations. 
All mice were between 6-10 weeks of age and from both sexes. 
C57BL/6J mice 
C57BL/6J mice were purchased from Charles River laboratories, Sulzfeld, Germany. 
2D2 mice 
2D2 mice (also named TCRMOG mice) were generated and characterized in 2003 by 
Bettelli and colleagues. In 2D2 animals, 90-95 % of the CD4+ T cells express the transgenic 
TCR Vα 3.2/Vβ 11, which specifically recognizes the MOG35-55 peptide. Around 4 % of the 
mice develop spontaneous EAE and the incidence of developing spontaneous optic neuritis is 
around 40 % (Bettelli et al., 2003). 
Th mice 
Th mice were created and characterized by Litzenburger and colleagues in 1998. For 
the generation of the mice, the VDJ region of the hybridoma 8-18C5 was inserted into the 
regular location of the rearranged variable (V) gene of the Ig heavy (H) chain. In Th mice (also 
named IgHMOG mice), 30-40 % of B cells express transgenic IgH chains, resulting in high 
production of MOG-specific pathogenic antibodies that can be found in the serum. Naïve 
transgenic animals do not develop spontaneous EAE or any sign of demyelination. However, 
the presence of the transgene accelerates and exacerbates EAE upon immunization when 
compared to wild type littermates (Litzenburger et al., 1998). For this thesis only 
heterozygous animals (Th/+) were used. 
OSE mice 
OSE mice characterized by Bettelli et al. and Krishnamoorthy et al. were generated by 
crossbreeding Th/Th mice with 2D2 animals (Bettelli et al., 2006, Krishnamoorthy et al., 
2006). OSE mice have MOG-specific T- and B cells and develop spontaneous EAE in 30-50 % 
of the animals. 
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Rag1-/- mice 
Rag1-/- mice were generated by Mombaerts and colleagues in 1992 and subsequently 
backcrossed to C57BL/6J mice. In these mice, the recombination activating gene-1 (RAG1) 
was mutated, resulting in reduced lymphoid organs accompanied by a complete absence of 
mature B and T cells (Mombaerts et al., 1992). 
Rag1-/- γc-/-mice 
Rag1-/- γc-/-mice were generated by crossbreeding of γc gene (also known as Il2rg gene) 
deficient mice (Cao et al., 1995) with Rag1 deficient mice (Mombaerts et al., 1992). These 
mice lack mature B cells, T cells and NK cells. 
Th/+ CCR2-/-mice 
Th/+ and chemokine receptor type 2 (CCR2-/-) mice were generated by crossbreeding 
of Th/Th mice with CCR2-/- mice (see 2.3.2). CCR2 deficient mice showed a severe 
impairment in leukocyte firm adhesion, extravasation and recruitment of inflammatory 
monocytes to sites of inflammation in vivo (Kuziel et al., 1997). 
Th/+ CD59a-/- mice 
Th/+ CD59a-/- mice were generated by crossbreeding of Th/Th mice with CD59a-/- mice 
(Holt et al., 2001) (see 2.3.2). CD59a is the major inhibitor of the membrane attack complex 
(MAC) formation. CD59a-/- mice are healthy and fertile but exhibited hemoglobinuria and 
intravascular spontaneous hemolysis, exacerbated upon administration of cobra venom 
factor (a recognized agent for triggering the depletion of the complement cascade) (Holt et 
al., 2001). CD59a-/- mice were provided by Prof. Dr. George Trendelenburg (Neurology 
Department, University Medical Center, Göttingen). 
OT-II mice 
OT-II [ovalbumin (OVA)-specific, MHC class II-restricted αβ TCR mice] mice were 
developed and characterized by Barnden and colleagues in 1998. In OT-II transgenic mice 
CD4+T cells are specific for the OVA323-339 peptide (Barnden et al., 1998). OT-II mice used in 
this thesis were a kindly provided by Prof. Michael Schön (Department of Dermatology, 
Venereology and Allergology, University Medical Center, Göttingen). 
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2.3.2  Breeding 
All mice used in this study were bred at the animal facility of the University Medical 
Center Göttingen, under specific pathogen free (SPF) conditions and backcrossed to 
C57BL/6J for more than 12 generations. Mice were kept in a controlled environment under 
12/12 hour light/dark cycles with access to water and food ad libitum. Experiments were 
performed in accordance with the European Communities Council Directive of 24 November 
1986 (86/EEC) and were approved by the Government of Lower Saxony, Germany (G 347.11, 
G 1005.12). 
2.3.3  Marmosets 
Common marmosets (Callithrix jacchus) from both sexes (2-4 years old, n=10) were 
bred at the German Primate Center (Göttingen, Germany). Depletion experiments of 
inflammatory monocytes in marmoset-EAE (see 2.4.4.2 for details) were conducted by PD 
Dr. Christina Schlumbohm (Neu Encepharm) under the guidelines of the European Council 
Directive of September 2010 (2010/63/EU) and Communities Council Directive 86/609/EEC, 
and approved by the Lower Saxony Federal State Office for Consumer Protection and Food 
Safety (LAVES), Germany. 
2.4  Methods 
2.4.1  Genotyping of genetically modified mice 
Genotyping of genetically modified mice and optimization of polymerase chain 
reaction (PCR) conditions were partially performed by Katja Schulz and Olga Kowatsch 
(Department of Neuropathology, University Medical Center Göttingen). The genotyping of 
the OT-II mice used in this thesis was performed at the Dermatology Department, University 
Medical Center Göttingen (protocol not described here). 
2.4.1.1 DNA extraction 
Tail biopsies were collected from 2D2, Th/+, Rag1-/-, Rag1-/- γc-/-, OSE, Th/+ CCR2-/- and 
Th/+ CD59a-/- mice at 3 weeks of age. For the extraction of genomic DNA, the tails were 
digested overnight in a mixture of 350 µl tail lysis buffer and 20 µl Proteinase K using a 
shaker (350 rpm, 56 °C). Samples were centrifuged (5 min, 13200 rpm) and the supernatants 
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were collected in new eppendorf tubes. For DNA precipitation 350 µl of isopropyl alcohol 
were added to each sample, thoroughly mixed and centrifuged again. Supernatants were 
discarded on a tissue and 500 µl of ethanol (70 %) were added followed by a last 
centrifugation step. The DNA pellet was dried during 10-15 min at 45 °C in a speed vacuum 
concentrator and resuspended in 100 μl bidistilled water. 
2.4.1.2  Polymerase chain reaction 
The composition of the PCR reactions for the genotyping of each transgenic mouse is 
described in Table 19. For additional details regarding the primers used see Table 13. All PCR 
reactions were run in a T3 thermocycler and the specific cycling conditions are described in 
Table 20. Ethidium bromide-stained PCR products were separated by electrophoresis on an 
agarose gel (2 % in TBE buffer) at 120 V for 60-90 min and the product length was evaluated 
using a 100 bp DNA ladder (Thermo Scientific) under UV light. 
For the genotyping of Rag1-/-γc-/- mice, two PCR reactions were performed: one for the 
RAG1 gene and one for the gene Il2rg (IL-2 receptor, gamma chain). Similarly, for OSE mice, 
two PCR reactions corresponding to Vα 3.2 TCR gene (2D2 mice) and Igh-J gene (Th mice) 
were ran. Finally, for Th/+ CCR2-/- and Th/+ CD59a-/- mice, a PCR reaction to identify the 
presence of the Igh-J gene was performed in addition to the corresponding ones for Ccr2 
and Cd59a genes. 
Table 19: Composition of PCR reactions for genotyping of transgenic mice 
PCR reaction components 
Gene 
Vα 3.2 TCR Igh-J RAG1 Il2rg Ccr2 Cd59a 
Betaine Q - - - 1.1 µl - - 
DNA template 5 µl 5 µl 1 µl 1.5 µl 2 µl 1 µl 
dNTP Mix (10 mM) 0.4 µl 0.4 µl - - 1 µl 2 µl 
dNTP Mix (2.5 mM) - - 0.5 µl 2.2 µl - - 
Go Taq® DNA pol. Buffer (10X) - - - 2.2 µl - - 
Go Taq® DNA pol. Buffer (5X) 4 µl 4 µl 2.5 µl - 5 µl 4 µl 
Go Taq® DNA polymerase 0.1 µl 0.1 µl 0.1 µl - 0.2 µl 0.1 µl 
H2O, bidistilled 9.5 µl 8.5 µl 5.4 µl 9.15 µl 15.3 µl 12.3 µl 
MgCl2 - - - 1.1 µl - - 
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PCR reaction components 
Gene 
Vα 3.2 TCR Igh-J RAG1 Il2rg Ccr2 Cd59a 
Primers 0.5 µl each 0.5 µl 
each 
1.2 µl (fp) 
0.6 µl (rp) 
1 µl each 0.5 µl 
each 
0.2 µl 
each 
Red Taq® DNA polymerase - - - 0.75 µl - - 
Abbreviations 
Ccr2: chemokine (C-C motif) receptor 2; Cd59a: CD59a antigen; fp: forward primer; Igh-J: immunoglobulin 
heavy chain, joining region; Il2rg: IL-2 receptor, gamma chain; RAG1: recombination activating gene 1, rp: 
reverse primer; Vα 3.2 TCR: alpha chain 3.2 of the T cell receptor, variable region 
 
Table 20: Conditions of PCR reactions and identification of the products 
Gene Step 1 
(°C/sec) 
Step 2 
(°C/sec) 
Step 3 
(°C/sec) 
Step 4 
(°C/sec) 
Step 5 
(°C/sec) 
Step 6 
(°C/sec) 
Product size 
(bp) 
Vα 3.2 TCR 95/120 95/60 58/60 72/60 72/600 4/∞ tg 600-700 
Igh-J 95/120 95/60 61/60 72/60 72/600 4/∞ wt 150 
ko 100 
RAG1 94/120 94/60 58/45 72/45 72/120 4/∞ wt 474 
ko 530 
Il2rg 94/180 94/30 67/30 72/60 72/120 4/∞ wt 269 
ko 349 
Ccr2 94/180 94/45 59/45 72/60 72/600 4/∞ wt 180 
ko 450 
Cd59a 95/120 95/30 59/30 72/30 72/300 4/∞ wt 212 
ko 450 
Abbreviations: tg: transgene; wt: wild type; ko: knockout; ∞: infinite 
Note: Step 1: pre-denaturation; Step 2: denaturation; Step 3: annealing; Step 4: elongation; Step 5: final 
elongation; Step 6: Hold. Steps 2-4 are repeated for 30-35 cycles 
 
2.4.2  Experimental autoimmune encephalomyelitis 
EAE is the most common animal model of MS, used to study mechanisms of 
autoimmune CNS inflammation and tissue injury (Gran et al., 1999, Engelhardt, 2006, 
Boretius et al., 2012). 
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2.4.2.1  Induction and assessment of EAE 
EAE induction in mice 
EAE was induced in 2D2, C57BL/6J, Th/+, Th/+ CCR2-/-, Th/+ CD59a-/- and OSE mice. 
Therefore, mice were anesthetized by intraperitoneal (i.p.) injection of 100 µl/10 g of body 
weight of a xylazine/ketamine mixture (xylazine: 20 mg/kg; ketamine: 120 mg/kg). 2D2 mice 
were subcutaneously (s.c.) immunized with 200 µg/animal of MOG35-55 (myelin 
oligodendrocyte protein, peptide fragment 35-55) emulsified in complete Freund´s adjuvant 
(CFA) supplemented with 5 mg/ml Mycobacterium tuberculosis H37RA. For immunization of 
the remaining mice strains 100 µg recombinant rat MOG1-125/CFA (myelin oligodendrocyte 
protein, peptide fragment 1-125) were used. Mice were injected i.p. with 300 ng of pertussis 
toxin (PTX) dissolved in 200 µl PBS at the day of immunization and again 48 h after. Control 
animals were immunized with CFA only. 
EAE induction in common marmosets 
Common marmosets, (see 2.3.3) were immunized s.c. with 50 µg recombinant rat 
MOG1-125 emulsified in Freund´s adjuvant supplemented with 0.25 mg/ml Mycobacterium 
butyricum. 
The clinical course of EAE in common marmosets was recorded daily by a trained 
person using a neurological disability scale first reported by Villoslada and colleagues 
(Villoslada et al., 2000) and further developed by Boretius and colleagues (Boretius et al., 
2006). 
In mice, the clinical course of EAE was monitored daily starting on day 7 after 
immunization following a scoring system ranging from 0 (healthy) to 5 (death) detailed in 
Table 21. 
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Table 21: Clinical EAE score in mice 
Score Clinical signs 
0 Healthy, no clinical signs 
0.5 Partial paralysis of the tail 
1 Complete paralysis of the tail 
2 Beginning paralysis of the hind limbs; mouse can be turned on its back 
2.5 Strong paralysis of the hind limbs 
3 Complete paralysis of hind limbs; beginning paralysis of abdominal muscles 
3.5 Complete paralysis of abdominal muscles, beginning weakness of fore limbs 
4 Pronounced weakness or complete paralysis of fore limbs 
5 Dead 
 
For cortical lesion experiments (see 2.4.3), mice were intracortically injected on the 
second day of EAE. 
2.4.3  Generation of cortical lesions in the mouse 
For this purpose, a modification of the technique previously developed in our 
laboratory for the generation of cortical lesions in rats (Merkler et al., 2006b) was used. The 
method combines EAE immunization of the animals with a focal intracerebral injection of 
pro-inflammatory cytokines into the cortex. Figure 1 depicts a schematic representation of 
the experimental setup. 
 
Figure 1: General experimental setup for the generation of cortical demyelinated lesions in 
the mouse 
2.4.3.1  Focal intracerebral injection 
Mice were anesthetized by i.p. injections of ketamine/xylazine (10 µl/g of body 
weight). Once the mice were deeply anesthetized, heads were shaved, the scalp was opened 
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to expose the skull and the animals were immobilized in a stereotactic device. The exposed 
periosteum was disrupted with a scalpel and a 2 mm diameter hole was drilled on the right 
brain hemisphere [0.1 mm caudal to bregma, 0.2 mm lateral to the midline]. A fine, 
calibrated glass capillary with a diameter between 1-2 µm was inserted into the brain motor 
cortex (0.7 mm depth) and 2 µl of a mixture of 50 ng tumor necrosis factor-alpha (TNFα) and 
60 ng IFNγ were injected over a 3-5 min period. Monastral blue was added to the cytokine 
mixture to identify the injection site. In all immunized animals, focal intracerebral injections 
were done on the second day after clinical onset of EAE. Dr. Claudia Wrzos (Department of 
Neuropathology, University Medical Center Göttingen) performed most of the intracerebral 
injections. 
2.4.4  Depletion and blocking experiments 
In mice, all depletion and blocking experiments started at EAE onset unless stated 
otherwise. The efficiency of the depletion experiments was evaluated by flow cytometry 
analysis (see 2.4.7.3) immediately before the intracerebral cytokine injection and at the day 
of sacrifice. Brain and spinal cord tissue was collected for histopathological analysis on day 5 
post stereotactic injection. 
2.4.4.1  CCR2 inhibition in the mouse 
Immunized Th/+ mice received daily 4 mg/kg of the CCR2 inhibitor RS 504393 starting 
at EAE onset and until day 5 after the intracortical injection of cytokines (Figure 2). 
Therefore, the dosage was divided into two daily oral gavages of 40 µg from the inhibitor in 
200 µl of a mixture of dimethyl sulfoxide (DMSO) and 1 % sodium carboxymethyl cellulose 
(CMC) solution. A stock solution of the inhibitor (4 µg/µl) in DMSO and a 1 % CMC solution 
were prepared and mixed as follows: 10 µl stock solution/190 µl of 1 % CMC. Th/+ animals in 
the control group received only vehicle (DMSO/CMC mixture). 
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Figure 2: Schematic representation of CCR2 inhibition in Th/+ mice 
2.4.4.2  Monocyte depletion in marmosets 
For depleting inflammatory monocytes in marmosets with EAE, a humanized 
monoclonal mouse anti-human CCR2 antibody (named DOC-2 Fr-2) was used. Prof. Matthias 
Mack (Department of Internal Medicine, University Hospital Regensburg) developed and 
provided the mouse anti-human CCR2 antibody. This mouse anti-human CCR2 antibody was 
humanized by Dr. Eilish Cullen (Medical Research Council Technology, Lynton House, 
London, UK). 
For EAE experiments, the DOC-2 Fr-2 antibody was administered twice per week i.v. 
(5 mg/kg) from day 14-24 after immunization and once weekly thereafter until day 56. 
Marmosets in the control group received i.v. injections of a control isotype antibody (named 
AMBA) (see Figure 3). 
Figure 3: Schematic representation of the treatment protocol for the depletion of 
inflammatory monocytes in marmoset monkeys 
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2.4.4.3  Depletion of granulocytes in the mouse 
For the depletion of polymorphonuclear leukocytes, Th/+ mice received daily i.p. 
injections (400 µg/animal) of the depleting antibody anti-Ly6G (clone 1A8) (Daley et al., 
2008) or a control isotype (Clone 2A3) (Hermesh et al., 2012) according to Figure 4. 
 
Figure 4: Schematic representation of the granulocyte depletion protocol in Th/+ mice 
2.4.4.4  Depletion of natural killer cells in the mouse 
Th/+ mice were depleted from NK cells by daily i.p. injections of 300 µg/mouse of the 
mAb PK136 (anti-NK1.1) (Nierlich et al., 2010). Control Th/+ mice received the same dose of 
the control isotype antibody C1.18.4 (Lamere et al., 2011). Both antibodies were 
administered until day 4 post stereotactic injection and the animals were perfused 24 h later 
(see Figure 5). 
Figure 5: Schematic representation of the protocol for NK cell depletion in Th/+ mice 
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2.4.4.5  Blockade of the membrane attack complex in the mouse 
For blocking the formation of the membrane attack complex (MAC), Th/+ mice 
received 2 µg of the BB5.1 mAb against the mouse convertase C5 (C5) (Frei et al., 1987, 
Huugen et al., 2007) or a control IgG1 isotype (clone MOPC-21) (Pohar et al., 2013) as 
depicted in Figure 6. The antibodies were injected intracortically together with the 
inflammatory cytokines as described previously and mice were perfused on day 5 post-
injection. 
 
Figure 6: Schematic representation of the protocol to inhibit the formation of the MAC in 
Th/+ mice 
2.4.4.6  Blockade of leukocyte transmigration into the CNS 
To study the effect of hampering the transmigration of immune cells into the CNS in 
the model, the Natalizumab mouse analogue mAb PS/2 (Theien et al., 2001) was used. This 
rat IgG2b antibody directed against the mouse α4-integrin CD49d (also known as VLA-4), 
blocks the interaction between the CD49d receptor expressed on leukocytes and its ligand, 
the vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells. As a result, leukocyte 
migration into the CNS is inhibited (Yednock et al., 1992, Baron et al., 1993). Therefore, 
immunized Th/+ mice received daily 200 µg/animal i.p. injections (7 injections in total) of the 
PS/2 antibody or an anti-key limpet hemocynanine specific rat IgG2b control antibody (Noval 
Rivas et al., 2009) starting at EAE onset until day 4 after the intracerebral injection. 
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2.4.5  Adoptive transfer experiments 
EAE was induced in Rag1-/- and Rag1-/- γc-/- deficient mice by adoptive transfer of 
10 Mio activated MOG-specific T cells from 2D2 donor mice. Recipient mice were immunized 
s.c. with 10 µg MOG35-55/CFA 12 h after T cell transfer. 
10 Mio activated ovalbumin-specific T cells from OT-II mice and activated MOG-specific 
T cells from 2D2 animals were adoptively transferred into Rag1-/- mice. Recipient mice were 
immunized s.c. with 10 µg MOG35-55 or OVA323-339/CFA 12 h after T cell transfer. 
2.4.5.1  Isolation, cultivation and transfer of T cells into recipient mice 
For the isolation of T cells, donor mice were euthanized by cervical dislocation. The 
spleens were removed under aseptic conditions and smashed through a sterile cell strainer 
(70 µm) to obtain single cell suspensions. Splenocytes were collected in 50 ml tubes by 
flushing 10-15 ml of RPMIcomplete medium through the cell strainer and tubes were spun 
down for 10 min at 300 x g and 4 °C. Supernatants were discarded and the pellets were 
resuspended in 2 ml of BD Pharm LyseTM solution (pre-diluted 1:10 in bidistilled water). Lysis 
of red blood cells was performed for 3-4 min at room temperature (RT) and the reaction was 
stopped by adding 20 ml of cold RPMIcomplete. Cells were centrifuged again (same conditions 
as described above), the supernatants discarded and the cell pellet resuspended in 5 ml of 
RPMI. Cell viability and cell numbers were assessed in a Neubauer chamber using trypan 
blue solution (Strober, 2001). 
Splenocytes from 2D2 or OT-II mice were first expanded by plate bound anti-CD3 and 
anti-CD28 stimulation. For this purpose, 96 U-well plates were incubated overnight in a 
fridge with anti-CD3 antibody (4 µg/ml in PBS, clone 145-2C11). The plates were washed 
twice with 200 µl RPMI to remove unbound antibody and 2^105 splenocytes/well were 
added in 80 µl RPMI. 20 µl of RPMI containing 0.1 ng rm IL-12 and 0.1 µg anti-CD28 antibody 
(clone PV-1) were added to each well (final concentrations: 1 ng/ml IL-12; 1 µg/ml anti-CD28 
antibody). After 3 days, the splenocytes were transferred to 24 well plates and expanded by 
rm IL-2 (2 ng/ml). The cells were split every second day and RPMI with 4 ng/ml rm IL-2 was 
added. 10 days after CD3/CD28 stimulation. 1.5 Mio T cells were re-stimulated with 6 Mio 
30 Gy-irradiated splenocytes as APC and 15 µg/ml MOG35-55 or OVA323-339 peptide for 3 days 
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at 37°C/5 % CO2 in 24 well plates. The T cells were collected, washed twice with PBS, 
counted and 10 Mio T cell blasts in 200 µl PBS were injected i.p. into recipient animals. 12 h 
after the adoptive transfer, recipient mice were s.c. immunized with 10 µg MOG35-55 or OVA 
peptide and received a single i.p. injection of 300 ng PTX. 
2.4.6  Motor skill sequence (MOSS) test 
Male Th/+ and C57BL/6J mice (20 animals each) were trained during 2 weeks on an 
activity wheel with regularly spaced crossbars (training wheel) in which animals were 
allowed to run voluntarily. Next, mice were immunized s.c. with a subclinical dose of 10 µg 
recombinant rat MOG1-125/CFA. After immunization, animals were put back on the training 
wheel for 11 more days and then randomized according to their performance on the training 
wheel into comparable groups, which received stereotactic injections of either 2 µl PBS or 
inflammatory cytokines: 
- 10 Th/+ mice (intracerebral injection of PBS) 
- 10 Th/+ mice (intracerebral injection of cytokines) 
- 10 C57BL/6J mice (intracerebral injection of PBS) 
- 10 C57BL/6J mice (intracerebral injection of cytokines) 
One day after surgery, mice were put onto a “complex activity wheel” with irregularly 
spaced crossbars and the maximum running speed in rpm/min (Vmax) and the accumulative 
distance in meters reached daily by the animals were continuously recorded using the 
LabVIEWTM-based custom software. The Vmax was expressed in percent, relative to the 
highest velocity reached at the end of the training in the normal activity wheel. Mice were 
perfused 8 days after stereotactic injections and brains and spinal cords were collected for 
histology. 
2.4.7  Analysis of immune cells ex vivo 
To define the immune cell composition of cortical lesions in Th/+ mice and to check 
depletion efficiency of different cell populations in transgenic mice as well as in the 
marmosets, blood and cortex were collected and analyzed ex vivo by multicolor flow 
cytometry. The markers defined for the identification of each cell population by flow 
cytometry are depicted in Table 22. 
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Table 22: Classification of the cell populations identified by flow cytometry analysis 
Cell population Specific surface and intracellular markers 
T cells CD45+ CD3+ 
CD4 T cells CD45+ CD3+ CD4+ 
Regulatory T cells CD45+ CD3+ CD4+ CD25+ FoxP3+ 
CD8 T cells CD45+ CD3+ CD8+ 
Inflammatory monocytes CD45+ CD11b+ Ly6Chigh CCR2+ Ly6G- 
Granulocytes CD45+ CD11b+ Ly6G+ 
Microglia CD45int CD11bint Ly6C- Ly6G- 
NK cells CD45+ CD3- NK1.1+ Nkp46+ 
B cells CD45+ CD19+ 
 
2.4.7.1  Preparation of peripheral blood leukocytes 
For preparation of PBMC from mice, 2-3 drops of blood were collected by puncture of 
the superficial temporal vein (facial vein) into a tube containing 300 µl of 1 mM EDTA, 
thoroughly mixed and transferred into a FACS tube. 1 ml of FACS buffer was added and 
tubes were centrifuged at 300 x g, 10 min at 4 °C. Cells were resuspended in 1 ml of FACS 
buffer/EDTA 1 mM. 
2.4.7.2  Preparation of CNS mononuclear cells from murine cortex 
Immunized Th/+ mice, received stereotactic injections of inflammatory cytokines. Two 
days later, animals were perfused with ice cold PBS, brains were dissected and cortical tissue 
was carefully separated from white matter using a scalpel and razor blades. Cortical 
fragments were isolated from each mouse, put into individual sterile 70 µm cell strainers for 
mechanical disruption and collected in 50 ml tubes containing DMEM high glucose without 
supplements. 
The cortical tissue collected was subjected to enzymatic digestion for 45 min at 37 °C 
with 2.5 mg/ml Collagenase D and 1 mg/ml DNAse I in DMEM high glucose without 
supplements. Digestion was stopped by adding 10 ml DMEM with 2 % FCS and the digested 
tissue was centrifuged at 1200 rpm/10 min. The pellet was resuspended in 5 ml 37 % Percoll 
and carefully overlaid on 5 ml 70 % Percoll. The Percoll gradient was centrifuged at 
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1600 rpm/25 min and the interphase was removed. The cells of the interphase were washed 
2 times with FACS buffer and subjected to flow cytometry analysis. 
2.4.7.3  Flow cytometry 
All flow cytometry data were acquired on a FACS CantoTM II device using the BD 
FACSDiva Software 6.1.2 and processed with the FlowJo Software 7.61. Unless stated 
otherwise, staining procedures were performed in 96 well round bottom plates; 
centrifugation of the plates was performed at 300 x g for 5 min at 4 °C and 200 µl FACS 
buffer were used for each washing step. 
2.4.7.3.1  FACS staining procedure of peripheral blood leukocytes 
FACS tubes containing PBMC suspensions were centrifuged at 300 x g, 8 min at 4 °C. 
Pellets were resuspended in 50 µl of FACS buffer containing 1 µl anti-CD16/CD32 blocking 
antibody against Fc receptors and incubated for 15 min at 4 °C. Up to eight fluorochrome-
labeled antibodies (0.4 µl of each antibody) were added and incubated for 15 min at 4 °C. 
Cells were washed with FACS buffer/EDTA 1 mM by centrifugation at 300 x g for 8 min at 
4 °C. One further washing step was performed and erythrocytes were subsequently lysed 
using BD FACSTM lysing solution. For the lysis, the pellet was resuspended in 1 ml of BD 
FACSTM lysing solution and incubated 4 min at RT. Lysis was stopped by adding 4 ml of FACS 
buffer, and cells were spun down as described previously, washed with 1 ml FACS buffer and 
resuspended in 100 µl of FACS buffer for flow cytometry analysis. 
2.4.7.3.2  FACS staining procedure of CNS mononuclear cells 
Cells were blocked by anti-CD16/CC32 antibodies (1 µl in 50 µl FACS buffer) for 15 min 
at 4 °C. Up to eight fluorochrome-labeled antibodies were added to each well (0.4 µl of each 
antibody) and incubated for 15 min. After two washing steps with FACS buffer, cells were 
resuspended in 100 µl FACS buffer and analyzed by flow cytometry. 
Intracellular FoxP3 staining 
After staining the cell surface molecules (see 2.4.7.3.2), the cells were fixed for 45 min 
in 100 µl FoxP3 fixation concentrate diluted 1:4 in FoxP3 dilution buffer. Next, the fixed cells 
were washed once with permeabilization buffer (10X concentrate diluted 1:10 in bidistilled 
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water) and then incubated for 35 min with 100 µl of FoxP3 antibody diluted 1:200 in 
permeabilization buffer. Cells were then washed once with 200 µl Perm/WashTM buffer and 
once with FACS buffer and analyzed by flow cytometry. 
2.4.8  Blood brain barrier permeability experiments 
To study temporary changes in permeability of the BBB in the model, Th/+ mice, 
healthy or previously immunized with rMOG1-125, were intracortically injected and perfused 
6 h and 24 h post-injection. One hour before perfusion, mice received i.v. injections of 
100 µg/g of body weight of an albumin-fluorescein isothiocyanate conjugate (FITC-albumine) 
dissolved in sterile NaCl. 
2.4.9  Histology 
2.4.9.1  Perfusion, fixation and paraffin embedding of the tissue 
After receiving lethal doses of narcosis, mice and marmosets were transcardially 
perfused with cold PBS followed by 4 % paraformaldehyde (PFA). For mice, perfusion was 
performed at different time points: 24 h, day 5, day 10, day 20 and day 40 after intracerebral 
cytokine injection. Post-fixation of the tissue was carried out in PFA 4 % for 48 h. Brains and 
spinal cords were dissected and later embedded in paraffin. Human biopsies were fixed in 
buffered formalin and subsequently embedded in paraffin blocks. 
2.4.9.2  Cutting and mounting of paraffin-embedded sections 
Sections of 1-3 µm thickness were cut from paraffin blocks using a sliding microtome, 
then mounted on glass slides and dried overnight. The presence of Monastral blue dye 
(described in 2.4.3.1) in the sections was used for visual identification of the injection site. 
2.4.9.3  Deparaffinization and rehydration of paraffin-embedded sections 
Before proceeding with any staining protocol, the slides must be deparaffinized and 
rehydrated. Therefore, paraffin slides were put in an oven for at least 1 h at 56 °C and then 
gradually deparaffinized by subsequent immersion in xylene followed by immersion in 
aqueous alcoholic solutions as follows: 
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1. Xylene: 4 x 5 min 
2. Isopropyl alcohol/Xylene: 1 x 2 min 
3.  Isopropyl alcohol (100 %): 2 x 3 min 
4. Isopropyl alcohol (90 %): 1 x 3 min 
5. Isopropyl alcohol (70 %): 1 x 3 min 
6. Isopropyl alcohol (50 %): 1 x 3 min 
7. Distilled water to rinse: 30 sec 
After the stainings were performed, slides were dehydrated following a reverse order 
of the previous steps described above and mounted in DePex medium. 
2.4.9.4  Histochemical stainings 
2.4.9.4.1  Luxol Fast Blue/periodic acid-Schiff staining 
Luxol fast blue (LFB) is a copper phthalocyanine dye that is attracted to the bases 
found in the lipoproteins of the myelin sheath, allowing myelin visualization (in blue). The 
periodic acid-Schiff (PAS) staining is a method for detecting polysaccharides and is used as a 
counterstain in combination with LFB. In this thesis, spinal cord sections from Th/+ CCR2+/+ 
and Th/+ CCR2 -/- mice as well as from marmosets treated with the CCR2 depleting antibody 
(DOC-2 Fr) or control isotype, were stained with LFB/PAS for assessing the extent of 
demyelination. 
Sections were deparaffinized (see 2.4.9.3) until step 4 (90 % isopropyl alcohol), placed 
in a cuvette with LFB solution and incubated overnight at 60 °C. Sections were transferred to 
90 % isopropyl alcohol, then individually differentiated by short dipping in 0.05 % lithium 
carbonate solution, 70 % isopropyl alcohol, and eventually washed with distilled water. For 
the PAS counterstaining, the sections were immersed in 1 % acetic acid for 5 min, washed 
for 5 min in running tap water and rinsed in distilled water afterwards. Next, sections were 
incubated for 20 min in Schiff´s reagent, washed for 5 min with running tap water, immersed 
for 2 min in Mayer´s hemalaum solution and rinsed in distilled water. Sections were then 
counterstained in 1 % HCl-alcoholic solution, blued for 5 min in running tap water, 
dehydrated and mounted. 
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2.4.9.4.2  Chloroacetate esterase staining 
Esterases are a family of different enzymes found in cells of granulocytic lineage. In the 
specific esterase Kit used (Sigma), naphthol AS-D chloroacetate is the substrate for the 
specific esterase enzyme present in granulocytes, which is hydrolyzed, and as a result, a free 
naphthol compound is released. This compound is then coupled with a diazonium salt, 
forming colored deposits (bright pink) at sites of enzymatic activity. For identification and 
quantification of granulocytes in this thesis, chloroacetate esterase (CAE) staining was 
performed according to the manufacturer´s instructions on paraffin-embedded sections 
from Th/+ mice treated with the granulocyte depleting antibody 1A8 or the control isotype 
2A3 (see 2.4.4.3). The brain samples stained with CAE corresponded to 24 h after the 
stereotactic injection. 
Briefly, the slides were deparaffinized, rinsed in distilled water and preheated in PBS at 37 °C 
for 30 min-1 h. Sections are incubated for 2 h at 37 °C in a working solution, consisting of 2 % 
sodium nitrite, 2 % Fast Corinth salt, 10 % TrizmalTM buffer and 2 % naphtol AS-D 
chloroacetate and washed with distilled water. Nuclei were counterstained briefly in 
Mayer’s hemalum for 30 sec, washed 10 min with tap water for differentiation (blued) and 
mounted using Aquatex medium. 
2.4.10  Immunohistochemistry 
Immunohistochemistry (IHC) is a method used to label determined proteins in tissue 
sections by using specific antibodies. First, tissue sections are deparaffinized and then 
rehydrated before applying the primary antibody. Then a secondary antibody conjugated to 
an enzyme (e.g.: avidin, streptavidin, peroxidase) is applied and the antibody-antigen 
interaction is visualized after adding a substrate specific for the enzyme. Once the cleavage 
of the substrate occurred, a localized colored precipitate can be observed under light 
microscopy. Other methods consist in using a secondary antibody conjugated to a 
fluorophore substance, and the detection in this case is done using fluorescent microscopy. 
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2.4.10.1  Antigen retrieval of paraffin-embedded tissue 
In some cases, antigens in the tissue can be masked due to the fixation with PFA 
requiring a retrieval step before immunohistochemical staining can proceed. All antibodies 
used for paraffin-embedded tissue in this thesis required heat-induced epitope retrieval (Shi 
et al., 2001). For heat-induced antigen retrieval, different buffers were used: sodium citrate 
buffer 10 mM pH 6, Tris-EDTA buffer 1 mM pH 9 or HCl buffer 4 mM pH 2.5. The sections 
were heated in a microwave (800 watt) 5 times for 3 min each, refilling the cuvettes 
between each cycle alternatively with bidistilled water or the corresponding retrieval buffer. 
Sections were then allowed to cool down for 20 min and rinsed 3 times with bidistilled 
water. Detailed information on antibodies and the retrieval buffers is listed in Table 9. 
2.4.10.2  Processing, cutting and fixation of frozen tissue 
Frozen tissue sections (cryosections) from mouse brain were used for NKp46/CD3 
double IHC. For this purpose, animals were perfused as described previously (see 2.4.9.1) 
but only with cold PBS. Brains were dissected, cut in 2-3 mm coronal sections, mounted on 
OCT medium and frozen in isopentane pre-cooled in liquid nitrogen to form cryo-blocks. If 
not processed the same day, cryo-blocks were stored at -80 °C until needed. Next, frozen 
tissues were cut into 6 µm sections using a cryostat at -20 °C, mounted on glass slides and 
frozen at -80 °C until used. On the day of the histochemical staining, sections were air dried 
for at least 30 min at RT to prevent the tissue from detaching. Sections were subsequently 
fixed using an appropriate organic solvent: 100 % ethanol for 1 h at RT, ether for 30 min at 
RT or acetone for 10 min at -20 °C. Afterwards, slides were air-dried for 10 min, rehydrated 
for 10 min in PBS and stained with the corresponding primary antibodies. 
2.4.10.3  Labeled streptavidin biotin (LSAB) method 
For most of the immunohistochemical stainings used in this thesis the LSAB method 
was used, which relies on the strong affinity of streptavidin for the vitamin biotin. Once the 
sections (frozen or paraffin-embedded) were deparaffinized/fixated and antigen retrieval 
was performed where required, the slides were incubated with a 3 % hydrogen peroxide 
solution in PBS for 20 min at 4 °C or 0.3 % hydrogen peroxide/PBS for 10 min (for frozen 
tissue sections). This step suppresses endogenous peroxidase activity in the tissue. Slides 
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were then washed 3 times in PBS and incubated for 20 min at RT in blocking buffer (10 % 
FCS/PBS) to block unspecific antibody binding before the primary antibody was added onto 
the sections. For the CD14 staining, 10 % goat serum was used as blocking buffer. Next, the 
primary antibody, diluted in blocking buffer (see Table 9) was added and sections were 
incubated over night at 4 °C in a humid chamber. 
After overnight incubation slides were rinsed 3 times in PBS and the corresponding 
biotinylated secondary antibody diluted in blocking buffer was applied onto the slides for 1 h 
at RT (see Table 10). The excess of non-bound antibody was removed by washing 3 times 
with PBS. For amplification of the signal, streptavidin conjugated to horseradish peroxidase 
(HRP) diluted in blocking buffer (1:1000) was added and incubated for 1 h at RT. Slides were 
washed 3 times with PBS, developed using a 3,3’ diaminobenzidine (DAB) solution (Table 2) 
which yields a dark brown end product and the reaction was controlled under a light 
microscope. After a washing step with distilled water, slides were counterstained in Mayer’s 
hemalaum for 30 s. Slides were washed again with distilled water, differentiated in 1 % HCl 
solution, blued in tap water for 7 min, dehydrated and mounted as described above (see 
2.4.9.3). 
Following this basic procedure double IHC can be performed. In this case, after 
developing the first reaction with DAB, sections are washed with distilled water or PBS and 
put in the appropriate blocking buffer in which the primary antibody against the second 
antigen of interest has to be diluted. From this step on, the same protocol described above is 
followed but the new product is developed using a different chromogen (e.g.: fast blue for 
the GrB/CD3 double staining in MS biopsies). 
2.4.10.4  Tyramide signal amplification method 
For assessment of cortical lesions in the model, brain sections from injected mice were 
stained for MBP. To achieve an optimal intensity of the staining, the method of tyramide 
signal amplification was used. In this method, the tyramide portion of tyramine-protein 
conjugates is covalently attached to the area around the protein of interest through a 
peroxidase-catalyzed reaction. This process takes place after first applying a primary 
antibody and a secondary-HRP conjugate. At the end, an amplified signal is obtained by 
addition of an antibody-enzyme or a –fluorophore conjugate directed against the protein 
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portion of the tyramine-protein conjugate formed in the previous step. To this end, a 
Tyramide Signal Amplification kit (see Table 12) was used following the recommendations of 
the provider. 
2.4.10.5  Fluorescent immunohistochemistry 
Immunofluorescence was used to simultaneously visualize two antigens of interest in 
the tissue, for example: CCR2/CD14 in MS biopsies or NKp46/CD3 in Th/+ mice cryosections. 
Therefore, sections were pretreated as described previously (see 2.4.9.3, 2.4.10.1, 2.4.10.2), 
washed 3 times with PBS, blocked with 10 % goat serum and incubated with the primary 
antibodies at 4 °C over night. Subsequently, slides were washed 3 times in PBS and 
incubated with the corresponding fluorochrome-labeled antibodies (see Table 11) for 30-
60 min at RT in darkness. The intensity of the staining was monitored using a fluorescence 
microscope (Olympus BX51). After three washing steps with PBS, nuclei were counterstained 
with DAPI (1:10000 in PBS) for 15 min at RT. Slides were washed again 3 times in PBS, rinsed 
once in distilled water and mounted using fluorescence mounting medium (Dako, Germany). 
2.4.10.6  Immunohistochemical stainings in mice, marmosets and human tissue 
For detailed information on the antibodies used as well as the corresponding dilutions, 
etc., please refer to Table 9. 
Mice 
For evaluating cortical demyelination in mice, brain sections were immunostained for 
MBP and the signal was enhanced using a Tyramide Signal Amplification kit (Invitrogen) as 
described previously (see 2.4.10.4). 
To characterize inflammatory infiltrates in the lesions, T cells were immunolabelled 
with a rabbit anti-CD3 antibody, (DCS) and for microglia/macrophages using a rat antibody 
directed against Mac- 3 (clone M3/84). For the identification of mature oligodendrocytes 
and oligodendrocyte precursor cells (OPC) in cortical demyelinated areas, double IHC was 
performed combining a rabbit anti-- Tubulin polymerization promoting protein p25 
(TPPP/p25) antibody and a rabbit anti- Oligodendrocyte transcription factor 2 (Olig2) 
antibody respectively, on sections previously stained with a rat anti-rMOG antibody purified 
in the Institute of Neuropathology, Göttingen. Additional double IHC on MOG-stained 
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sections were performed for APP, a recognized marker of axonal damage and NeuN for 
identifying neurons. 
NK cells infiltrating the cortex of stereotactically injected Th/+ mice were 
immunolabelled in brain cryosections using the primary goat anti-mouse antibody 
NKp46/NCR1. To distinguish NK from NKT cells, double immunofluorescence labeling was 
done combining the antibody NKp46 with a rabbit anti-CD3 antibody (Dako) in frozen tissue 
sections. For visualizing NKp46, a secondary donkey anti-goat biotinylated antibody was 
added followed by incubation with a CyTM3-conjugated streptavidin antibody. The 
AlexaFluor® 488 goat anti-rabbit antibody was used to visualize the CD3 IHC, and nuclei were 
counterstained with DAPI. 
Finally, to measure the area of cortical FITC extravasation in Th/+ mice injected with 
the FITC-albumin conjugate (see 2.4.8), paraffin-embedded brain sections were 
immunostained with a rabbit anti-FITC antibody conjugated to HRP. 
Common Marmosets 
For assessing cortical demyelination in marmoset brains, paraffin-embedded tissue 
sections were immunostained for MBP and enhanced with tyramide as previously described 
for mice. 
Multiple sclerosis tissue 
To illustrate the inflammatory cells present in early cortical demyelinated lesions from 
MS patients, biopsy sections were stained with primary antibodies against MBP, CD3 and 
KiM1P (pan macrophage marker). To confirm the presence of inflammatory monocytes in 
these early lesions, double immunofluorescence IHC for CD14 (mouse anti-CD14 antibody) 
and CCR2 (rabbit anti-CCR2 antibody E68) was performed. CyTM3-conjugated goat anti-
mouse antibody and AlexaFluor®488 antibody, respectively, were used for detection and 
nuclei were counterstained with DAPI. 
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Furthermore, granzyme B (GrB) and CD3 were co-immunolabelled to identify the 
presence of NK cells in early cortical demyelinated MS lesions. A biotinylated anti-mouse 
antibody for GrB and a goat anti-rabbit-AP antibody for CD3 were used for the detection. 
The GrB staining was developed using DAB as a chromogen and for CD3 Fast Blue was used 
(Boorsma, 1984). 
2.4.11  Morphometric analysis 
All measurements of tissue areas were carried out using the Image J software v. 1.46 in 
previously captured TIFF images. MBP-immunostained sections from mice and marmosets 
were used to evaluate the extent of cortical demyelination comprising subpial and 
intracortical perivascular demyelinated areas. In mice, images were acquired using a 40x 
magnification objective in a light microscope (Olympus BX51) equipped with a digital 
camera. Coronal sections of marmoset brains were scanned using a Keyence BIO REVO BZ-
X710 microscope and compound images were generated (BZ-II analyzer software) from 
single pictures. In mice, subpial demyelinated areas were measured only in the ipsilateral 
(injected) brain hemisphere, while perivascular cortical demyelination was assessed in both 
ipsi- and contralateral cortex. Perivascular demyelinated areas were reported in mm2 and 
subpial demyelination in percentage (%). The latter was calculated as follows: 
𝑠𝑢𝑏𝑝𝑖𝑎𝑙 𝑑𝑒𝑚𝑦𝑒𝑙𝑖𝑛𝑎𝑡𝑖𝑜𝑛 ( %) =
𝑠𝑢𝑏𝑝𝑖𝑎𝑙 𝑑𝑒𝑚𝑦𝑒𝑙𝑖𝑛𝑎𝑡𝑒𝑑 𝑎𝑟𝑒𝑎
𝑎𝑟𝑒𝑎 𝑜𝑓 𝑖𝑝𝑠𝑖𝑙𝑎𝑡𝑒𝑟𝑎𝑙 𝑐𝑜𝑟𝑡𝑒𝑥
× 100 
Quantitative analyses were performed on day 5 after intracerebral injection unless 
stated otherwise. All cell quantifications were done at a 400x magnification and cell densities 
(cells/mm2) were determined using a 10x10 ocular morphometric grid. In C57BL6/J mice, the 
densities of p25+, Olig2+ and NeuN+ cells were assessed in the ipsilateral cortical layers 
extending from cortical layer I to II/III, whereas for Th/+ mice the counts were restricted to 
subpial demyelinated areas present across the same layers. Axonal damage (APP+ axons) 
was assessed in both hemispheres around perivascular demyelinated areas. 
Polymorphonuclear neutrophil (PMN) cell densities were quantified on CAE stained sections 
from Th/+ mice, treated with the granulocyte depleting antibody 1A8 or the control isotype 
2A3, at 24 h after the intracerebral injection. Granulocytes were quantified in the cortical 
parenchyma and along the meninges. For assessment of BBB permeability in our model, 
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cortical areas positively-immunostained for FITC were measured with Image J using an 
incorporated color deconvolution plugin (Ruifrok and Johnston, 2001). The threshold for 
quantifying the intensity of the brown (DAB) channel was set at (0; 150). For analysis of 
macrophages/activated microglia in mouse brain, the number of intracortical Mac3 + 
perivascular cuffings was counted in both hemispheres. For quantification of demyelinated 
areas in spinal cord sections of mice and marmosets stained with LFB-PAS (see 2.4.9.4.1), 
images were acquired from at least eight transversal spinal sections of each animal, 
demyelination within the white matter was measured and reported as percent of total white 
matter demyelinated. 
Human quantitative data comprised the assessment of Ki1MP+ macrophages/activated 
microglia and T cell (CD3) densities in early MS cases using a morphometric grid as described 
for the mice. Immunopositive cells were counted in regions where subpial cortical 
demyelination was present as well as in normal appearing cortical regions (NAGM) when 
available. At least five separate visual fields were quantified for each cortical region within 
each sample, and densities were reported as cells/mm2. 
2.4.12  qRT-PCR analysis 
To evaluate if the expression of genes related to inflammatory monocytes were 
differentially regulated between intracortically injected Th/+ CCR2+ and Th/+ CCR2-/- mice, 
animals were perfused with PBS two days after injection, the ipsilateral cortex at the 
injection site was carefully separated from the WM and put in QIAzol Lysis Reagent. RNA was 
isolated using the RNeasy Micro Kit (Qiagen) and transcribed into complementary DNA 
(cDNA) using the High Capacity RNA-to-cDNATM Kit (Life Technologies). From the cDNA 
obtained, 12.5 ng/PCR reaction were used and quantitative PCR (qPCR) was run on the 
1Q5TM Real Time PCR Detection System (BIO-Rad) using a standard qPCR Core Kit. The 
following FAM labeled primers/probes were selected for intron-spanning: Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (Mm99999915_g1), TNF-α (Mm00443258_m1), 
NOS2/iNOS (Mm00440502_m1) and CCL2 (Mm00441242_m1) (see Table 14). The 
expression levels of TNF-α, Nitric oxide synthase 2 (NOS2)/ Inducible-nitric oxide synthase 
(iNOS) and Chemokine (CC motif) ligand 2 (CCL2) were indicated as percent of the expression 
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of GAPDH (housekeeping gene). The qRT-PCR analysis was done in cooperation with Dr. 
Franziska Paap (Institute of Neuropathology, University Medical Center Göttingen). 
2.4.13  Data analysis and statistics 
Normality tests were applied to all data sets (D´Agostino and Pearson omnibus 
normality test) using GraphPad Prism 5.01 software. If samples followed a normal 
distribution, an unpaired t-test was used to compare two groups. In the absence of 
normality, a non-parametric test (Mann-Whitney U test) was applied. For comparisons 
between three or more groups one-way analysis of variance (ANOVA) followed by a post-hoc 
test: Dunn´s Multiple Comparison test (when all groups were compared to each other) or 
Dunnett's Multiple Comparison test (when groups were compared against a control) was 
selected. A p<0.05 was considered to be significant. Unless otherwise specified, all results 
are shown as mean ± s.e.m. 
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3 RESULTS 
3.1 Analysis of inflammatory infiltrates in cortical demyelinated MS 
lesions 
To address a possible contribution of adaptive and innate immune cells to cortical 
lesion pathogenesis in MS, brain biopsies from eight patients exhibiting inflammatory 
demyelination compatible with MS and featuring cortical demyelination were analyzed (see 
Table 18, Material and Methods section). 
Cortical demyelinated areas in MPB-immunostained sections showed inflammatory 
hallmarks identified by the presence of few perivascular and parenchymal CD3+ T cells and 
KiM1P+ macrophages/activated microglia (Figure 7A). Cell densities were significantly higher 
in subpial cortical demyelinated areas when compared to cortical NAGM, especially for 
KiM1P+ phagocytes. Inflammatory monocytes, co-expressing CD14 and CCR2 were also 
observed by immunofluorescence IHC in the demyelinated cortex (Figure 7B). Additionally, a 
fraction of GrB+ CD3- cells which were mainly located around vessels and most likely 
represent NK cells were observed in sections double-labeled for these markers (Figure 7C). 
3.2  Assessment of cortical demyelination in Th/+, 2D2 and C57BL/6J 
mice 
To address whether pathogenic antibodies are required for the generation of cortical 
demyelinated lesions, mice received a stereotactic injection of pro-inflammatory cytokines 
(IFNγ and TNFα) into the motor cortex on day 2 after EAE onset. Three mouse lines were 
used: Th/+ mice (rMOG1-125 -immunized) in which demyelinating anti-MOG antibodies can be 
found in the serum, 2D2 T cell receptor transgenic mice (MOG35-55-immunized) which have a 
high frequency of MOG-specific T cells but no demyelinating antibodies and C57BL/6J mice 
(rMOG1- 125-immunized), which develop non-demyelinating antibodies to MOG peptides in 
response to immunization. 
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Figure 7: Adaptive and innate immune cells in cortical demyelinated MS lesions 
(A) Early MS biopsies showed an extensive loss of MBP in subpial cortical demyelinated (SCD) regions as well as 
increased numbers of KiM1P+ phagocytes and CD3+ T cells in comparison to cortical normal appearing grey 
matter (NAGM). Exemplary KiM1P+ cells and CD3+ T cells are marked by arrowheads and amplified in the 
corresponding insets. The dotted line in the MBP SCD image demarcates a cortical area of preserved myelin 
Data represent mean ± s.e.m. (SCD n=8, NAGM n=5, **p<0.01, Mann Whitney U test). (B) MS biopsy stained for 
CCR2 (green) and CD14 (red) showed the presence of perivascular CCR2+CD14+ inflammatory monocytes 
(white arrowheads) in recently demyelinated cortical lesions. (C) GrB+CD3- NK cells (arrowheads) are part of 
the perivascular inflammatory infiltrates in recently demyelinated cortical MS lesions. The asterisk points to the 
lumen of a cortical vessel. CD3 (blue), GrB (brown). Scale bars, 100 µm (MBP), 50 µm (KiM1P and CD3) and 
20 µm (CD3/GrB). 
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3.2.1  Cortical demyelination was only observed in Th/+ mice 
Cortical demyelinated areas (subpially and around intracortical inflamed vessels) were 
only observed in Th/+ mice and peaked on day 5 after stereotactic injection (Figure 8). 
Demyelinated lesions were not confined to the ipsilateral cortex, but extended to the 
contralateral, non-injected hemispheres. This observation differs from the findings in the 
Lewis rat model (Merkler et al., 2006b), where the contralateral hemisphere remained 
unaffected. 
 
Figure 8: Cortical demyelination requires a pathogenic antibody response against MOG 
MBP IHC (brown color) on day 5 after injection illustrates cortical demyelination in Th/+ mice (top), but not in 
2D2 (middle) or C57BL6/J mice (bottom). The dotted line in the overview of the Th/+ mouse brain delineates 
the subpial cortical demyelinated areas in both, the ipsi- and contralateral hemispheres. Subpial demyelination 
is quantified in the left bar graph. Perivascular cortical demyelination is depicted in the panels on the right, 
(black asterisks mark the lumen of the vessel) and quantified in the right bar graph. Red squares in the brain 
overviews mark the areas enlarged in the subpial ipsilateral photographs. Red stars identify the injection site. 
Scale bars, 1 mm (brain overviews), 100 µm (subpial ipsilateral and contralateral) and 50 µm (perivascular). 
Data of three independent experiments are presented as mean ± s.e.m. (2D2 n=3, C57BL/6J n=5, Th/+ n=13, 
*p<0.05, **p<0.01, one-way ANOVA followed by Dunnʼs Multiple Comparison post hoc analysis). 
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3.2.2  Loss of oligodendrocytes and axonal damage in cortical demyelinated 
lesions of Th/+ mice 
Cortical demyelination on day 5 after stereotactic injection was accompanied by a 
significant reduction of Olig2+ oligodendroglial cells and specially of p25+ mature 
oligodendrocytes in Th/+ mice (Figure 9). In addition, APP+ axons were observed almost 
exclusively in Th/+ mice around perivascularly demyelinated vessels. Neuronal densities 
(NeuN IHC) were not reduced. 
 
 
Figure 9: Oligodendrocyte loss and axonal damage occur in cortical demyelination in the 
mouse 
Assessment of mature oligodendrocytes (p25+), oligodendroglial cells including OPC (Olig2+), axonal damage 
(APP+ axons) and neurons (NeuN+) in cortical demyelinated areas of Th/+ (top) and C57BL/6J mice (bottom). 
Cell markers (blue), MOG (brown). Cells were quantified in subpial demyelinated areas for Th/+ mice and 
normally myelinated layers I and II/III for C57BL/6J mice. A significant reduction in the densities of p25+ and 
Olig2+ cells was observed in subpial demyelinated areas of Th/+ mice. Increased axonal damage (APP+ axons) 
was found around perivascularly demyelinated vessels. Neuronal densities were similar in both groups. 
Arrowheads indicate exemplary APP+ axons, p25+ and Olig2+ cells, shown in detail in insets. Scale bars, 100 µm 
(representative for p25/MOG, Olig2/MOG and APP/MOG images), 20 µm (corresponding insets) and 50 µm 
(NeuN/MOG). Dotted lines in the images mark the border between demyelinated and normally myelinated 
areas in the cortex. Graphs show data from two independent experiments presented as mean ± s.e.m. (Th/+ 
n=7, C57BL/6J n=5, *p<0.05, **p<0.01, Mann Whitney U test). 
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3.2.3  Time course of cortical demyelination and inflammation in Th/+ mice 
Time course experiments in Th/+ mice were performed to address the question 
whether cortical demyelination resolves rapidly, as previously shown in the cortical lesion 
model in Lewis rats (Merkler et al., 2006b). Compared to Lewis rats which showed significant 
remyelination already on day 14 after lesion induction, Th/+ mice remyelinated somewhat 
slowlier (Merkler et al., 2006b). Significant remyelination was observed on day 20 after 
injection for perivascular areas and on day 40 for subpial regions (Figure 10A). A reduction of 
macrophages and T cell infiltration was observed over time, paralleling remyelination. 
Already on day 10, the amount of Mac-3+ perivascular cuffings decreased, reaching 
significance from day 20 on. The T cell density was significantly decreased on day 40 after 
injection (Figure 10B). 
Figure 10: Time course of inflammation and demyelination in cortical demyelination in 
Th/+ mice 
(A) Time course of cortical demyelination. MBP IHC assessment of the extent of subpial (upper panels, scale bar 
100 µm) and perivascular demyelinated lesions (lower panels, scale bar 50 µm) on days 5, 10, 20 and 40 post-
injection. Significant perivascular remyelination was observed on day 20, significant subpial remyelination on 
day 40 (bar graphs on the right). Asterisks mark parenchymal vessels. Data of two independent experiments 
are presented as mean ± s.e.m. (day 5 n=13, n=6 day 10, 20, 40, *p<0.05, **p<0.01, one-way ANOVA followed 
by Dunn´s Multiple Comparison post hoc analysis). (B) Time course of perivascular macrophage (Mac-3+) 
cuffings (left graph) and T cells (CD3+) (right graph), on day 5, 10, 20 and 40 after stereotactic injection. Data of 
two independent experiments shown as mean ± s.e.m. (Mac-3: day 5-40 n=6 each, CD3: day 5, 20 n=6, 
day 10, 40 n=5). One-way ANOVA followed by Dunn´s Multiple Comparison post hoc analysis,*p<0.05, **p<0.01 
(statistical significance depicted in the graphs refers to the post hoc analysis). 
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3.2.4  Motor skill sequence (MOSS) test 
To assess whether cortical demyelinated lesions lead to subtle motor dysfunctions or 
impair the adaptation to complex motor tasks, Th/+ and C57BL/6J mice were subjected to 
the MOSS test (see 2.4.6, Figure 11A) (Liebetanz and Merkler, 2006). 
Animals were first trained on a regular wheel and later Th/+ and C57BL/6J mice were 
each randomized into two comparable groups which received PBS or cytokines 
stereotactically into the motor cortex (Figure 11B). While non-demyelinated cytokine- or 
PBS-injected C57BL/6J mice adapted to complex wheels comparably, the adaptation of 
cytokine- injected Th/+ mice was transiently impaired compared to PBS-injected Th/+ mice 
between day 4-6 post injection. Interestingly, running speed as well as running distance of 
cytokine-injected Th/+ mice significantly dropped at the time when inflammatory 
demyelination was most extensive. Of note, cytokine injections alone were not sufficient to 
impair the adaptation of C57BL/6J mice to complex wheels as shown in Figure 11B. 
3.3  Assessment of early cortical inflammatory infiltrates in Th/+ 
mice 
Leukocytes from the cortex of injected Th/+ mice were isolated on day 2 after 
stereotactic injection and characterized by flow cytometry. Cortical inflammatory infiltrates 
were predominantly composed of T cells, inflammatory monocytes, microglia cells, 
granulocytes, NK cells and few B cells (Figure 12). 
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Figure 11: Adaptation to complex motor tasks is transiently impaired in cytokine injected 
Th/+ mice 
(A) Schematic representation of the motor skill sequence (MOSS) test. (B) Th/+ mice (top graphs) injected with 
cytokines (red circles) or PBS (black circles) as well as C57BL/6J mice (bottom graphs), cytokine-(blue squares) 
or PBS-injected (black squares) were put into complex wheels after receiving stereotactic cortical injections. 
The relative maximal velocity (Vmax) and the running distance were recorded. The dotted vertical line in the 
graphs represents the day of the stereotactic injection. Representative data of one out of two independent 
experiments is presented as mean ± s.d. (n=10 mice/group, *p<0.05, **p<0.01, one-way ANOVA followed by 
Dunn´s Multiple Comparison post hoc analysis). 
Figure 12: Composition of the early 
inflammatory infiltrates in the cortex 
of Th/+ mice 
Cortical leukocytes from Th/+ mice (n=3) were 
analyzed by flow cytometry on day 2 post 
injection. The amount of the different immune 
cells identified is represented as percentage of 
the total numbers of CD45+-leukocytes. Data 
are presented as mean ± s.e.m. 
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3.4  Characterization of the immune cell players required for cortical 
demyelination 
NK cells, granulocytes and macrophages can exert antibody dependent cell cytotoxicity 
(ADCC) and, therefore, might contribute to the pathogenesis of cortical demyelinated lesions 
in Th/+ mice. To address the relevance of each cell type, mice deficient for inflammatory 
monocytes (Th/+ CCR2-/-) were generated and PMN and NK cells were depleted by specific 
antibodies. To study the role of complement-dependent cytotoxicity (CDC) in the formation 
of cortical demyelination, Th/+ mice deficient for CD59a were generated and the 
complement cascade was blocked in Th/+ mice, using a C5 blocking antibody. These 
experiments aimed at defining the immunological requirements for the development of 
cortical demyelinated lesions. 
3.4.1  Role of inflammatory monocytes in cortical demyelination 
To assess if inflammatory monocytes are required for cortical inflammatory 
demyelination in our model, Th/+ CCR2+/+ and Th/+ CCR2-/- mice were immunized with 
rMOG1-125 and stereotactically injected on day 2 after EAE onset. Disease severity was similar 
in both groups; however, in line with previous reports CCR2-deficient animals developed EAE 
(Gaupp et al., 2003) at a later time point (Table 23). 
Table 23: Clinical EAE data of Th/+ CCR2+/+ and Th/+ CCR2-/- mice 
Genotype Sample size Day of EAE onset (mean± SD) Maximum EAE severity (mean± SD) 
Th/+ CCR2+/+ n=13 11.2 ± 1.1 3.3 ± 0.5 
Th/+ CCR2-/- n=5 15 ± 1 3.2 ± 0.3 
Statistical analysis: EAE onset: ***p<0.001 (Unpaired T test). Disease severity: p=0.46 (Mann Whitney 
U test) 
In Th/+ CCR2-/- mice, the recruitment of inflammatory monocytes to the cortex was 
significantly impaired, as reflected in the FACS analysis performed on day 2 after the 
stereotactic injection (Figure 13A). In contrast, in Th/+ CCR2+/+ mice CCR2+Ly6Chi-
inflammatory monocytes represented more than 50 % of all CD45+CD11b+Ly6G- monocytes 
isolated from cortical tissue. In line with these findings, a significant reduction of 
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monocytes/macrophages was observed in the cortex of Th/+ CCR2-/- mice when assessing 
the number of Mac-3+ perivascular cuffings on day 5 after injection (Figure 13B). 
Furthermore, mRNA levels of monocyte-related genes, like TNFα and iNOS revealed a 
significant reduction in Th/+CCR2-/- deficient mice when compared to the Th/+ CCR2+/+ group 
(Figure 13C). Additionally, a trend towards a reduction in the gene expression of the CCL2 
ligand was observed in Th/+ CCR2-/- animals (p=0.0782). 
Figure 13: Impaired recruitment of inflammatory monocytes into the cortex of Th/+ CCR2-/- 
mice 
(A) Inflammatory monocytes in the cortex of Th/+ CCR2+/+ and Th/+ CCR2-/- mice were examined by flow 
cytometry on day 2 after injection and quantified (bar graph on the right). Ly6Chigh Ly6G- cells were significantly 
reduced in Th/+ CCR2-/- mice (n=7 mice/group). (B) Mac-3+ intracortical perivascular cuffings were significantly 
reduced in Th/+ CCR2-/- compared to Th/+ CCR2+/+ mice on day 5 post stereotactic injection (n=6 mice/group). 
Scale bar 50 µm. (C) Gene expression analysis of monocyte-related cytokines and chemokines in the cortex of 
Th/+ CCR2+/+ and Th/+ CCR2-/- mice on day 2 after stereotactic injection. The expression of TNF-α and iNOS was 
significantly reduced in Th/+ CCR2-/- mice. Results were normalized against GAPDH expression 
(n=5 animals/group). All quantitative data are expressed as mean ± s.e.m. and were analyzed by Mann Whitney 
U test (*p<0.05, **p<0.01, ***p<0.001). 
Cortical demyelination was also evaluated in Th/+ CCR2+/+ and Th/+ CCR2-/- mice by 
MBP IHC. Subpial and perivascular intracortical demyelination were substantially reduced in 
CCR2- /- deficient animals while Th/+ CCR2+/+ developed extensive demyelinated lesions 
(Figure 14A). In contrast to cortical demyelination, the extent of spinal cord demyelination 
was comparable between Th/+ CCR2-/-and Th/+ CCR2+/+ mice (Figure 14B). 
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Figure 14: Inflammatory monocytes are required for cortical demyelination 
(A) MBP IHC reflects a significant reduction in cortical demyelinated lesions (subpial, perivascular) in 
Th/+ CCR2 -/- (bottom) when compared to Th/+ CCR2+/+ mice (top). Red squares in brain overviews refer to the 
magnified area in subpial ipsilateral photographs. Dotted lines define subpial-demyelinated areas. Scale bars, 
1 mm (brain overviews), 100 µm (subpial ipsilateral) and 50 µm (perivascular). Data from three independent 
experiments are shown for Th/+ CCR2+/+ mice (n=13) and from two independent experiments for Th/+ CCR2-/- 
mice (n=5). (B) Representative histochemical staining of myelin (LFB/PAS) in transversal spinal cord sections of 
Th/+ CCR2+/+ (n=7) and Th/+ CCR2-/- mice (n=6) on day 5 after stereotactic injection. Both groups developed 
spinal cord demyelination to a similar extent. Scale bar, 200 µm. Data from two independent experiments. 
Quantitative data are expressed as mean ± s.e.m. (*p<0.05, **p<0.01, Mann Whitney U test). 
Next, the effect of CCR2 inhibition on lesions was investigated in Th/+ mice using the 
specific antagonist RS 504393 for CCR2 (see 2.4.4.1). While subpial cortical demyelination 
did not differ between Th/+ mice treated with vehicle or the CCR2 inhibitor, perivascular 
cortical demyelination was significantly reduced in the latter group (Figure 15). 
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Figure 15: CCR2-inhibition in Th/+ mice reduces perivascular demyelination 
Perivascular cortical demyelination in Th/+ mice was significantly reduced by the inhibition of CCR2 with 4 
mg/kg RS 504393 daily starting at disease onset, when compared to vehicle treated animals while subpial 
cortical demyelination remained unaltered. Red squares in brain overviews immunostained for MBP refer to 
the magnified area in subpial ipsilateral photographs. Dotted lines define subpial-demyelinated areas. Scale 
bars, 1 mm (brain overviews), 100 µm (subpial ipsilateral) and 50 µm (perivascular). Data are expressed as 
mean ± s.e.m. (Th/+ vehicle n=4, Th/+ CCR2 inhibitor n=6, *p<0.05, Mann Whitney U test). 
3.4.1.1  Cortical demyelination in marmosets is reduced by depletion of 
inflammatory monocytes 
To translate our results in the mouse model into a potential treatment option for 
cortical demyelination in MS, we treated marmosets with EAE a humanized monoclonal 
antibody against CCR2 (DOC-2 Fr-2). Depleting inflammatory monocytes in marmosets 
starting 2 weeks after immunization led to a moderate reduction of subpial and a significant 
reduction of perivascular cortical demyelination (Figure 16A). Interestingly, the extent of 
demyelination in the spinal cord did not differ between the two groups (Figure 16B). 
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Figure 16: Reduction of cortical demyelination in marmosets depleted of inflammatory 
monocytes by a novel, humanized anti-CCR2 antibody 
(A) Coronal brain sections immunostained for MBP (brown). Subpial cortical demyelinated regions (black 
dotted lines) and perivascular intracortical demyelinated areas (red lines) are delineated. Graphs show a 
moderate reduction of subpial cortical demyelination in marmosets depleted of inflammatory monocytes 
accompanied by a significant reduction of perivascular intracortical demyelination. (B) Representative images 
of transversal spinal cord sections stained with LFB/PAS show similar extents of demyelination in both groups. 
Scale bars, 1 cm (brain overviews), 500 µm (spinal cord sections). Data are expressed as mean ± s.e.m. (n=5 
animals/group, *p<0.05, Mann Whitney U test). 
3.4.2  Role of granulocytes in cortical demyelination 
To define whether PMN are relevant for cortical demyelination, Th/+ mice were 
injected with a selective granulocyte-depleting antibody directed against Ly6G (Clone 1A8) 
(Daley et al., 2008) (see 2.4.4.3). 
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Depletion efficiency was assessed by flow cytometry in the blood (before stereotactic 
injection) and in cortical tissue (24 h after stereotactic injection, when PMN numbers where 
highest in untreated mice) (Figure 17A). FACS plots for 1A8 antibody-treated animals show a 
significant reduction in granulocyte numbers at the time point assessed when compared to 
Th/+ mice treated with the control isotype antibody 2A3. Additionally, CAE histochemistry 
was performed in brain tissue 24 h after the stereotactic injection and granulocytes were 
quantified in the cortical parenchyma and meninges (Figure 17B). A significant reduction of 
meningeal granulocytes was observed in Th/+ mice treated with the anti-Ly6G antibody and 
almost no positive cells were detected in the cortical parenchyma. 
Figure 17: Granulocyte depletion in Th/+ mice 
(A) The efficiency of PMN depletion was determined by flow cytometry in the blood (left dot plot, before 
stereotactic injection) and cortex (right dot plot, 24 h after stereotactic injection). Granulocytes were 
significantly reduced in the compartments analyzed in the depleted animals (Th/+ 1A8). Data represent two 
independent experiments (Blood: Th/+ 2A3 Ab, n= 8; Th/+ 1A8 Ab, n=7; Cortex: Th/+ 2A3 Ab, n= 4; Th/+ 1A8 
Ab, n=5). (B) Representative brain sections of Th/+ mice stained with CAE histochemistry 24 h after stereotactic 
injection. A significant reduction in granulocyte numbers (dark pink cells) along the meninges was observed in 
granulocyte-depleted Th/+ mice (1A8 Ab). Granulocyte numbers in the cortical parenchyma did not differ 
between the groups. Scale bar, 50 µm (n=4 animals/group). Quantitative data are expressed as mean ± s.e.m. 
(*p<0.05, ***p<0.001, Mann Whitney U test). 
Nevertheless, the extent of cortical demyelination on day 5 after intracerebral cytokine 
injection was similar in both groups as observed in MBP immunostained sections (Figure 18), 
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arguing against a relevant contribution of granulocytes to the generation of cortical 
demyelinated lesions. 
 
Figure 18: Granulocyte depletion does not affect the extent of cortical demyelination 
Representative MBP immunostained sections of Th/+ mice treated with the 1A8 granulocyte depleting 
antibody or control isotype on day 5 post stereotactic injection. The extent or cortical demyelination was not 
affected by the depletion of granulocytes. Red squares in brain overviews mark the magnified areas in the 
subpial ipsilateral photographs; black dotted lines define subpial demyelinated areas; asterisks mark the lumen 
of parenchymal vessels. Scale bars represent 1 mm (brain overviews), 100 µm (subpial/ipsilateral panels), and 
50 µm (perivascular panels). Graphs show data of two independent experiments (Th/+ 2A3 Ab, n=6, Th/+ 
1A8 Ab, n=8). All quantitative data are expressed as mean ± s.e.m. (*p<0.05, ***p<0.001, Mann Whitney U 
test). 
3.4.3  NK cells contribute to perivascular cortical demyelination 
To assess the role of NK cells in cortical demyelination, Th/+ mice were depleted of NK 
cells before stereotactic injection. Therefore, the antibody PK136 targeting the NK1.1 
receptor on the surface of NK cells was used (see 2.4.4.4).FACS analysis of blood (before 
stereotactic injection) and cortical tissue (24 h after stereotactic injection) showed that NK 
cell numbers were significantly reduced in Th/+ mice treated with the NK-depleting antibody 
PK136, when compared to the control isotype group (Figure 19A). While the extent of 
subpial demyelinated lesions was similar between both experimental groups, there was a 
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significant reduction in perivascular cortical demyelinated areas in NK-depleted animals 
(Figure 19B). Additional immunohistochemical stainings in non-depleted mice confirmed a 
predominant perivascular localization of NK cells in the inflamed cortex (Figure 19C, D). 
 
Figure 19: Role of NK cells in cortical demyelination 
(A) NK depletion efficiency in Th/+ mice analyzed in the blood (before stereotactic injection) and cortical tissue 
(24 h after stereotactic injection) by FACS analysis. Data of two independent experiments are shown (Th/+ 
C1.18.4 Ab n=3, Th/+ PK136 Ab n=4; unpaired T test, Welch´s correction). (B) Perivascular cortical 
demyelination was significantly reduced in Th/+ mice depleted of NK cells (PK136 Ab) on day 5 post stereotactic 
injection. (n=7 animals/group, Mann Whitney U test). Scale bars, 1 mm (brain overviews), 100 µm 
(subpial/ipsilateral) and 50 µm (perivascular). Red squares in brain overviews mark the magnified areas in the 
subpial ipsilateral photographs; dotted lines delineate subpial cortical demyelinated areas. (C) Representative 
IHC of perivascularly located NK cells (NKp46, arrowheads) in the cortex of non NK cell-depleted Th/+ mice. 
Scale bar, 50 µm. Asterisks mark the lumen of the vessels. (D) Representative immunofluorescence staining of 
perivascularly located NK cells (NKp46, red channel; white arrowhead) showed no co-localization with CD3 
(green channel), confirming them being NK, but not NKT cells. Nuclei were counterstained with DAPI (blue 
channel). Scale bar, 10 µm. All quantitative data are expressed as mean ± s.e.m. (*p<0.05). 
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3.4.3.1  NK cells participate in perivascular cortical demyelination, if the MOG-
specific antibodies are of the IgG2a subclass 
To support further the relevance of NK cells for cortical demyelination, EAE was 
induced in Rag1-/- mice and Rag1-/- γc-/- mice by the adoptive transfer of activated MOG-
specific 2D2 T cells (see 2.4.5). One day after disease onset mice received 1.5 mg of the 
demyelinating anti-MOG antibody Z2 (IgG2a subclass) i.v. and were stereotactically injected 
with cytokines. Animals were perfused 5 days later, and the cortical demyelinated lesions 
were quantified (Figure 20A). Subpial cortical demyelination did not differ between Rag1-/- 
and Rag1-/-γc-/- mice, but perivascular cortical demyelination was significantly reduced in the 
latter group (Figure 20B). 
If the demyelinating anti-MOG antibody 8-18C5 (IgG1 subclass) was injected instead of 
the Z2 antibody, perivascular demyelination did not differ between the groups, and the 
demyelinated areas were smaller than those generated by using the Z2 antibody (Figure 
20C). 
3.4.4  Influence of the complement system on cortical demyelination 
To address whether the complement system contributes to cortical demyelination, the 
generation of the MAC in Th/+ mice was blocked. To this end, the BB5.1 antibody against the 
mouse convertase C5, or a control isotype were injected intracerebrally together with the 
standard mixture of inflammatory cytokines in diseased Th/+ mice which had been 
immunized previously (Figure 6). This antibody inhibits the activity of the C5 convertase and 
consequently the cleavage of C5 into C5a and C5b fragments. 
Additionally, Th/+ mice deficient for CD59a, the main inhibitor of the MAC on 
oligodendrocytes, were generated. We hypothesized that the extent of demyelination might 
increase in response to a less controlled classical complement pathway. 
In the presence of the BB5.1 antibody, subpial demyelination was significantly reduced 
in Th/+ mice when compared to the group which received the control isotype (Figure 21A). 
Perivascular cortical demyelination, in contrast, was similar in both groups. CD59a-deficiency 
in Th/+ mice did not modulate the extent of cortical demyelination (Figure 21B). 
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Figure 20: The contribution of NK cells to perivascular demyelination depends on the 
subclass of the pathogenic antibody 
(A) Schematic representation of adoptive transfer experiments in Rag1-/- and Rag1-/-γc-/- mice. (B) 
Representative MBP IHC of Rag1-/- (top) and Rag-/- γc-/- mice (bottom) adoptively transferred with 2D2 T cells 
and stereotactically injected with the pathogenic demyelinating anti-MOG antibody Z2. Quantifications 
revealed a significant reduction of perivascular cortical demyelination in NK cell-deficient mice while subpial 
cortical demyelination was similar in both groups (Rag1-/- n=5, Rag1- /- γc-/- n=4). Scale bars, 1 mm (brain 
overviews), 100 µm (subpial/ipsilateral) and 50 µm (perivascular). Red squares in the brain overviews mark the 
magnified areas in the subpial ipsilateral photographs; dotted lines delineate subpial demyelinated areas. (C) 
Quantification of perivascular cortical demyelination on MBP-immunostained sections of Rag1-/- and Rag1-/- γc-/- 
mice injected with the demyelinating anti-MOG antibody 8-18C5 (IgG1 subclass) did not show any differences 
between the groups (Rag1-/- n=5, Rag1-/- γc-/- n=4). All data are expressed as mean ± s.e.m. (*p<0.05, Mann 
Whitney U test). 
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Figure 21: Complement dependent cytotoxicity contributes to subpial cortical 
demyelination 
(A) Representative MBP IHC of stereotactically injected Th/+ mice which additionally received an intracerebral 
injection of the BB5.1 antibody, inhibiting C5 (top) or an isotype control (bottom) antibody. Quantification of 
demyelinated areas showed a significant reduction of subpial cortical demyelination in the group treated with 
the BB5.1 antibody. Data represent two independent experiments (9 mice/group, *p<0.05, unpaired T-test). (B) 
MBP IHC of Th/+ CD59a+/+ and Th/+ CD59a-/-mice intracerebrally injected with inflammatory cytokines showed 
that CD59a deficiency did not modulate the extent of cortical lesions in the model (n=6 mice/group, Mann 
Whitney U test). Red squares in the brain overviews mark the magnified areas in the subpial ipsilateral 
photographs and dotted lines define the respective subpial demyelinated areas. Asterisks point to the lumen of 
parenchymal vessels. Scale bars 1 mm (brain overview panels), 100 µm (subpial/ipsilateral panels) and 50 µm 
(perivascular panels). All quantitative data are presented as mean ± s.e.m. 
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3.4.5  Role of T and B cells in cortical demyelination 
To determine whether T and B cells are required to induce cortical inflammatory 
demyelination, several experiments were designed in Rag1-/- and OSE mice. First, the 
demyelinating anti-MOG antibody 8-18C5 or a control isotype antibody were injected into 
Rag1-/- healthy mice (Figure 22A) and cortical demyelination was assessed 5 days after 
stereotactic injection. 
 
Figure 22: T cells are dispensable for subpial but not for perivascular demyelination 
(A) Schematic representation of the experimental setup. (B) IHC for MBP on day 5 after stereotactic injection of 
8-18C5 or control antibody transferred Rag1-/- mice. Healthy Rag1-/- mice, which received 8-18C5 Ab developed 
subpial but not perivascular demyelinated lesions. Red squares in brain overviews mark the magnified areas in 
the subpial ipsilateral photographs and dotted lines define the respective subpial demyelinated areas. Asterisks 
point out the lumen of parenchymal vessels. Scale bars 1 mm (brain overview panels), 100 µm 
(subpial/ipsilateral panels) and 50 µm (perivascular panels). Data are expressed as mean ± s.e.m. and represent 
two independent experiments for Rag1 -/- mice (Ctrl. Ab, n=9) and Rag1-/- (8-18C5 Ab, n=8), *p<0.05, unpaired 
T-test. 
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A significant extent of subpial lesions was observed only in mice that had received the 
8-18C5 antibody, implying that T cells and antigen presenting function of B cells are 
dispensable for the generation of subpial demyelinated lesions. Perivascular cortical 
demyelination was completely absent in Rag1-/- mice (Figure 22B). The same was true if the 
8-18C5 antibody (IgG1 isotype) was replaced by the Z2 antibody (IgG2a subclass) (data not 
shown), which demonstrates that NK cells fail to induce perivascular cortical demyelination 
in the absence of activated T cells. 
3.4.5.1  T cells are required for perivascular cortical demyelination 
To address whether T-cell specificity as well as their activation state influence 
perivascular cortical demyelination, the extent of cortical lesions was compared between 
healthy Th/+ and OSE mice. It is worth noting that OSE healthy mice harbor non-activated 
MOG-specific T cells, in addition to the MOG-specific antibodies also present in Th/+ mice. 
The assessment of lesions 5 days after stereotactic injection showed that subpial 
demyelination was present to a comparable extent in healthy Th/+ and OSE mice, whereas 
perivascular cortical demyelination was barely observed (Figure 23). 
 
Figure 23: Assessment of cortical demyelination in healthy OSE and Th/+ mice 
Quantitative assessment of subpial and perivascular cortical lesions in Th/+ healthy (n=5) and OSE healthy mice 
(n=6), did not reveal any differences between the groups. Data are expressed as mean ± s.e.m. and were 
analyzed by Mann Whitney U test. 
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If, however, healthy and diseased-OSE mice, immunized with rMOG1-125, were 
compared, perivascular but not subpial demyelination was significantly increased in sick 
animals where MOG-specific T cells were activated (Figure 24A). 
To exclude a potential bias due to different antibody titers or antibody isotypes in 
diseased versus healthy OSE mice, cortical demyelination was assessed in diseased and 
healthy Rag1-/-mice, adoptively transferred with 2D2 or OT-II T cells respectively (see 2.4.5). 
Both experimental groups received 1.5 mg of the demyelinating anti-MOG antibody 8-18C5 
i.v. before stereotactic injection (see schematic representation in Figure 24B). 
As expected, subpial demyelination was similar in both 2D2 and OT-II transferred 
animals, but perivascular cortical demyelinated lesions were significantly larger in mice 
transferred with 2D2 T cells (Figure 24B). These findings indicate that encephalitogenic T 
cells are required for perivascular cortical demyelination in the presence of a pathogenic 
antibody, but are dispensable for subpial cortical demyelination. 
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Figure 24: Influence of T cell activation and specificity on perivascular cortical 
demyelination 
(A) Schematic representation of the experimental setup in OSE healthy vs OSE immunized mice (left). MBP IHC 
(right) demonstrates a significant increase in perivascular cortical demyelination in OSE immunized mice (n= 8) 
when compared to OSE healthy mice (n=4). Subpial demyelination did not differ between the groups. 
(B) Schematic representation of the experimental setup in adoptively transferred Rag1-/- mice. 2D2 or OT-II T-
cells were transferred into Rag1-/- mice, and animals received 1.5 mg of the 8-18C5 antibody i.v. before 
intracortical cytokine injection. Quantification of cortical demyelination on MBP-immunostained brain sections 
showed barely any perivascular cortical demyelination in mice which received OT-II T-cells (grey bars) instead 
of MOG-specific 2D2 T-cells (orange bars). Subpial demyelination was comparable in both groups. Data of two 
independent experiments are shown, n=6 (Rag1-/-, 2D2 Tc + 8-18C5) and n=12 (Rag1-/-, OT-II Tc + 8-18C5). Red 
squares in brain overviews mark the magnified areas in the subpial ipsilateral photographs; dotted lines define 
the respective subpial demyelinated areas. Asterisks point to the lumen of parenchymal vessels. Scale bars 
represent 1 mm (brain overview panels), 100 µm (subpial/ipsilateral panels), and 50 µm (perivascular panels). 
All quantitative data are expressed as mean ± s.e.m. and analyzed by Mann Whitney U test, *p<0.05. 
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3.4.6  Encephalitogenic T cells increase the permeability of intracortical vessels 
to FITC-albumin 
To assess BBB permeability and thus the influx, e.g. of pathogenic serum antibodies, in 
the present model, the cortical extravasation of FITC-albumin was measured in Th/+ mice 
(healthy or immunized) at 6 h and 24 h after stereotactic injection (see 2.4.8). 
FITC-albumin extravasation was detected in subpial cortical areas already 6 h after 
intracortical cytokine injection, being more significant in immunized Th/+ mice (Figure 25). 
At this early time point, no signs of albumin extravasation from intracortical vessels were 
detected in any of the groups. 24 h after lesion induction, subpial FITC-albumin extravasation 
was comparable in both groups, whereas extravasation from intracortical vessels was much 
more pronounced in diseased Th/+ mice, harboring activated, encephalitogenic T cells. 
Figure 25: Extravasation of FITC-albumin from intracortical vessels requires activated, 
encephalitogenic T cells 
Representative brain sections from Th/+ mice (healthy or immunized) FITC-immunostained 6 h and 24 h after 
stereotactic injection. Dotted lines define the areas analyzed for cortical FITC-albumin extravasation (brown 
signal). Subpial FITC extravasation was significantly increased in diseased Th/+ mice 6 h after injection, reaching 
comparable levels in both groups at 24 h. FITC-albumin extravasation from intracortical vessels was first 
observable 24 h after lesion induction, and was significantly increased in diseased Th/+ animals. Data are 
expressed as mean ± s.e.m. (Th/+ mice healthy, n=4; Th/+ mice diseased, n=5; *p<0.05, Mann Whitney U test). 
Scale bar, 500 µm. 
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3.4.7  VLA-4 blockade does not decrease cortical demyelination 
To assess the effect of blocking leukocyte entrance into the CNS on the extent of 
cortical demyelination, the Natalizumab mouse analogue antibody PS/2 was used (see 
2.4.4.6). This antibody recognizes the α4-integrin chain (CD49d) of VLA-4 on the surface of 
leukocytes, impeding the interaction with the corresponding ligand (VCAM-1) on the surface 
of endothelial cells. 
Interestingly, no reduction of cortical demyelination was observed in animals treated 
with the PS/2 antibody when compared to the control isotype group (Figure 26). 
Quantification of subpial (left) and perivascular (right) cortical demyelination on MBP-immunostained sections 
from stereotactically injected Th/+ mice in which VLA-4 was blocked. No significant differences were found 
regarding the extent of subpial or perivascular cortical demyelination in Th/+ mice systemically treated with the 
PS/2 antibody (n=6) when compared to mice treated with control isotype antibody (n=5). Data are expressed as 
mean ± s.e.m. (One-way ANOVA, Dunnett's Multiple Comparison Test). 
Figure 26: Influence of VLA-4 blockade on cortical demyelination 
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4 DISCUSSION 
4.1 The inflammatory component present in cortical demyelinated 
MS lesions may contribute to cortical pathology 
Cortical demyelination is a prominent feature in chronic progressive MS (Peterson et 
al., 2001, Bo et al., 2003a, Bo et al., 2003b, Kutzelnigg et al., 2005) that has been associated 
with disease progression and cognitive impairment in the patients (Calabrese et al., 2012). In 
post-mortem tissue from MS patients, cortical demyelinated areas can even exceed those of 
WM demyelination (Bo et al., 2003b). Furthermore, cortical demyelination has been also 
found in 38 % of biopsied patients in early stages of the disease (Filippi et al., 2010, 
Lucchinetti et al., 2011), and the majority of the lesions depicted are inflammatory at this 
time point (Lucchinetti et al., 2011, Popescu et al., 2011). 
In the present study, the analysis of MS biopsy tissue featuring subpial cortical 
demyelinated areas revealed the presence of inflammatory infiltrates (T cells and 
macrophages/microglia) in line with previous reports (Lucchinetti et al., 2011, Popescu et al., 
2011, Rodriguez et al., 2014). Moreover, the significant increase of microglia and 
macrophage activation in subpial cortical demyelinated areas confirmed the recent 
evolution of the lesions and their inflammatory signature (Rodriguez et al., 2014). The 
inflammatory phenotype reported in early cortical lesions was further reinforced by the 
presence of inflammatory monocytes co-expressing CD14 and CCR2 in two of the biopsies 
assessed in our study (MS cases 3 and 6, see Table 18). CCR2 is expressed in human “classical 
monocytes” (CD14++CD16-, phagocytic function) and in “intermediate monocytes” 
(CD14++CD16+, inflammatory function) (Ancuta et al., 2003). Interestingly, CCR2+ 
intermediate monocytes have been proposed as pathogenic cellular players in inflammatory 
disorders like Crohn’s disease (Grip et al., 2007) and cardiovascular diseases (Shantsila et al., 
2011). 
NK cells and cytotoxic T lymphocytes use the perforin/granzyme pathway as a main 
mechanism to kill pathogen-infected cells and tumor cells (Russell and Ley, 2002, Lieberman, 
2003). The expression or the absence of CD3 in cells positive for GrB was used to 
differentiate cytotoxic T cells (CD3+ GrB+) from NK cells (CD3- GrB+) in the present study 
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(Inverardi et al., 1991). In the biopsies analyzed for this work, CD3- GrB+ NK cells were 
identified in the meninges, in demyelinated WM regions and cortical demyelinated tissue, 
frequently in close proximity to cortical vessels. This is in line with recent findings in post-
mortem tissue of SPMS patients presenting more active than chronic lesions (2 cases out of 
12), where few NK cells were identified in demyelinated cortex and WM lesions, often 
located near blood vessels (Durrenberger et al., 2012). 
In summary, the findings in MS biopsies confirm that cells from both the adaptive and 
innate immune response are present in early cortical demyelination and may contribute to 
cortical lesion pathogenesis at this early stage. 
4.2  Cortical demyelination in Th/+ mice reflects the different cortical 
demyelinated lesions found in MS 
The mouse model of cortical demyelination developed in this thesis is based on a 
demyelinating anti-MOG antibody response in 8-18C5 knock-in (Th/+) mice (Litzenburger et 
al., 1998). In Th/+ mice, around 30 % of the transgenic B cells can bind MOG and high titers 
of MOG-specific antibodies are found in the serum of naïve animals. Naïve Th/+ mice do not 
develop neither spontaneous neurological disease, nor demyelination. Upon immunization 
with rMOG, the mature transgenic B cells differentiate to plasma cells that secrete MOG-
specific IgG antibodies, of both IgG1 and IgG2a subclasses indicative of isotype switching 
(Litzenburger et al., 1998). Furthermore, Th/+ mice and 2D2 mice form the basis for the 
generation of the OSE mouse, which characteristically develops spontaneous autoimmune 
demyelination (Bettelli et al., 2006, Krishnamoorthy et al., 2006). 
In the present study, Th/+ mice exhibited well-demarcated areas of confluent cortical 
demyelination, not only restricted to the injected brain hemisphere, but also extending to 
the contralateral (non-injected) side. Cortical demyelinated lesions were triggered by the 
focal injection of IFNγ and TNFα (targeted lesion approach). Reproducible demyelinated 
lesions were obtained affecting subpial as well as intracortical perivascular areas of the 
brain, reflecting the cortical lesion types observed in MS (Peterson et al., 2001, Bo et al., 
2003b). In this model, subpial demyelinated lesions extended from the pia mater into 
superficial cortical layers (mostly until layer II/III).  
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Additionally, leukocortical lesions were observed in some of the mice, but they did not 
constitute the prime interest of the present work. 
Up to now, inflammatory cortical demyelination has been experimentally observed in 
marmoset monkeys (Pomeroy et al., 2005, Merkler et al., 2006a, Pomeroy et al., 2008, 
Kramann et al., 2015) and MHC congenic rats (Storch et al., 2006) immunized with rMOG. In 
rats, cortical demyelination depended on particular combinations of MHC class I and II alleles 
(Storch et al., 2006). Furthermore, Lewis rats immunized with subclinical doses of rMOG have 
been shown to develop demyelinating cortical lesions after receiving an intracortical injection 
of pro-inflammatory cytokines (Merkler et al., 2006b, Rodriguez et al., 2014). Our model was 
developed in some analogy – however with important modifications – to the rat model. 
In addition, cortical demyelination in the cerebral and cerebellar cortex has been 
reported in mice subjected to the cuprizone diet (Skripuletz et al., 2008, Skripuletz et al., 
2010). Though the cuprizone model is useful for studying the dynamics of de- and 
remyelination, this toxic demyelination model is independent of adaptive immune cells 
(McMahon et al., 2001, Praet et al., 2014, Salinas Tejedor et al., 2015), which are part of the 
inflammatory response seen in cortical demyelination in MS. 
4.3  Remyelination of cortical demyelination in Th/+ mice 
In the present model, a relatively rapid resolution of demyelination, paralleled by a 
reduction of inflammatory infiltrates in the tissue (T cells and microglia/macrophages) was 
observed, evidencing a successful reparative process as reported previously (Franklin et al., 
1997, Merkler et al., 2006b). Although in the present study remyelination was not assessed 
by electron microscopy, the lack of a detectable lesion in MBP IHC 40 days after lesion 
induction suggests efficient remyelination. Starting around day 10 after stereotactic 
injection, regions of thin myelin characteristically observed during remyelination increased 
with time, most obvious in subpial areas. Similar indications of effective cortical 
remyelination have been reported in MOG-immunized rats receiving an intracortical 
injection of pro-inflammatory cytokines (Merkler et al., 2006b), or in the subarachnoid space 
(Gardner et al., 2013), as well as in MS studies, where GM lesions remyelinated more 
efficiently than those in the WM (Albert et al., 2007, Chang et al., 2012). 
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A recent study comparing contiguous WM and GM in leukocortical lesions has revealed 
a significant preservation/generation of OPCs in the GM demyelinated areas. In addition, 
WM demyelinated areas, but not the cortical ones, exhibited a significant increase in 
reactive astrocytes and associated extracellular molecules that may inhibit oligodendrocyte 
production and myelination (Chang et al., 2012), providing an explanation for the higher 
remyelinating capacity observed in cortical areas. 
4.4  Myelin and oligodendrocyte pathology in cortical lesions in Th/+ 
mice 
Oligodendrocyte pathology in MS is variable, with studies reporting oligodendrocyte 
preservation in acute lesions (Raine et al., 1981, Lassmann, 1983, Lucchinetti et al., 1999, 
Rodriguez et al., 2014) or oligodendrocyte loss in newly forming lesions (Prineas et al., 1984, 
Barnett and Prineas, 2004). In the cortical demyelination model in Th/+ mice, a significant 
reduction of Olig2+ oligodendrocytes was observed in subpial demyelinated areas on day 5 
after stereotactic injection. Olig2 constitutes a transcription factor necessary for 
oligodendroglial development, expressed during the entire maturation process of 
oligodendrocytes (Mei et al., 2013). Additionally, mature oligodendrocytes (p25+) were 
significantly reduced in the same areas, probably accounting for the decrease in the total 
number of oligodendrocytes at this early time point. Nevertheless, remyelination was not 
compromised in the long term. It is possible that OPCs readily repopulated the lesions and 
differentiated into myelinating oligodendrocytes; alternatively, OPCs may have been spared 
from the pathological process, as suggested above. Further studies are required to delineate 
the time course of oligodendrocyte damage, proliferation, migration, and differentiation in 
this model. 
4.5  Axonal damage is present in cortical lesions in Th/+ mice 
Acutely damaged axons, immunopositive for APP, were observed in cortical 
demyelinated lesions in Th/+ mice on day 5 after stereotactic injection. APP is synthesized in 
the neuronal cell body and transported to the synapses via fast anterograde axonal 
transport (Koo et al., 1990). In acutely injured axons, axonal transport is disrupted, resulting 
in the accumulation of axonally transported proteins like APP (Ferguson et al., 1997).  
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In early MS, acute axonal damage has been associated with inflammation and 
macrophage infiltration (Kuhlmann et al., 2002). Part of the damaged axons may then 
transect and degenerate, thus leading to axonal reduction (Trapp et al., 1998). However, a 
proportion of APP+ axons will survive the insult and resume full functionality (Nikic et al., 
2011). 
The significant increase in APP+ axons observed in cortical demyelination in Th/+ mice 
is in line with studies in MS patients reporting the presence of axonal damage in cortical 
demyelinated lesions (Peterson et al., 2001, Kutzelnigg et al., 2005). 
4.6   Cortical demyelination in Th/+ mice exhibits neuronal 
preservation 
On day 5 after stereotactic injection, neuronal density in subpial demyelinated areas in 
Th/+ mice was not reduced. Regarding neuronal injury in MS, reports differ, ranging from 
substantial to little if any neuronal loss in cortical demyelination (Peterson et al., 2001, 
Wegner et al., 2006, Lassmann, 2010, Magliozzi et al., 2010, Lucchinetti et al., 2011). These 
differences may in part be due to different sensitivities of the methods applied, or result 
from the intrinsic heterogeneity of the lesions. The cortical demyelination model presented 
in this study, like several others (Merkler et al., 2006b, Gardner et al., 2013, Rodriguez et al., 
2014), reflects an acute inflammatory episode, in contrast to the chronic inflammatory 
process present in MS patients, which likely explains why a reduction in neuronal numbers is 
not observed in our model. 
4.7  Cortical demyelination transiently impairs the performance of 
Th/+ mice in the complex running wheel 
The motor skill sequence (MOSS) test was developed in 2006 (Liebetanz and Merkler, 
2006) and its use in different animals models allowed, e.g., the detection of functional 
impairments associated with demyelination of the corpus callosum in the cuprizone model 
(Liebetanz and Merkler, 2006), and with developmental disruptions in the internal granule 
layer of the cerebellum (Maloney et al., 2011). 
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In the present study, a transient behavioral impairment of Th/+ mice between days 4 
and 6 after cytokine injection into the motor cortex could be observed. The mice ran slowlier 
and covered less distance in the complex wheel than the control animals. The impairment in 
the cytokine-, but no PBS-injected Th/+ mice coincides with the time when the maximum 
amount of inflammatory cortical demyelination was observed in the model. C57BL/6J mice 
injected with cytokines or PBS performed similarly in the complex wheel, indicating that the 
injection of inflammatory cytokines alone is not sufficient to impair the adaptation to 
complex wheel running. 
4.8  The generation of subpial and perivascular cortical lesions is 
controlled by different immunological mechanisms 
 Cortical demyelination requires a pathogenic antibody response against MOG 
Confluent demyelination is a pathological hallmark of MS. In most EAE models, the 
formation of substantial areas of demyelination relates to a pathogenic antibody response 
against extracellular epitopes of myelin proteins (Linington and Lassmann, 1987, Piddlesden 
et al., 1993, Adelmann et al., 1995, Brehm et al., 1999, Genain et al., 1999, von Budingen et 
al., 2002, Bourquin et al., 2003, Storch et al., 2006). In line with this, in our model, cortical 
demyelination could be induced by intracortical stereotactic injection of pro-inflammatory 
cytokines in Th/+ but not in 2D2 or C57BL/6J mice. Th/+ mice are heavy chain knock-in mice 
for 8-18C5, a well-known demyelinating MOG-specific antibody (Linington et al., 1988, 
Kerlero de Rosbo et al., 1990, Linington et al., 1993, Litzenburger et al., 1998). While 
immunization of Lewis rats with rMOG1-125, which includes the extracellular part of MOG, 
induces demyelinating MOG-specific conformational antibodies (Adelmann et al., 1995), the 
antibody response of C57BL/6J mice to rat rMOG1-125 immunization is largely confined to 
linear peptides (Bourquin et al., 2003, Marta et al., 2005). A contribution of antibodies to 
demyelination in MS has been postulated by studies demonstrating myelin-specific 
antibodies in patient sera (Gaertner et al., 2004, Zhou et al., 2006, Brilot et al., 2009) as well 
as by Ig depositions and complement products in MS tissue (Diaz-Villoslada et al., 1999, 
Genain et al., 1999, Lucchinetti et al., 2000, Lassmann et al., 2001).  
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However, antibodies against MOG are only inconsistently found in MS patients, 
suggesting that the targets of pathogenic antibodies in MS still have to be identified. 
The pathogenic potential of demyelinating antibodies has been previously attributed 
to their ability to fix complement (CDC) (Piddlesden et al., 1993, Storch and Lassmann, 1997, 
Storch et al., 1998, Urich et al., 2006, Breij et al., 2008) or to induce ADCC (Desjarlais and 
Lazar, 2011). Both CDC and ADCC depend on the Ig subclass of the antibody in question. 
IgG2a and 2b constitute the most potent subclasses for activating effector functions of 
antibodies in mice following a hierarchical order: IgG2a ≥ IgG2b > IgG1 » IgG3 (Fossati-Jimack 
et al., 2000, Nimmerjahn and Ravetch, 2005, Aschermann et al., 2010). Since plasma cells in 
Th/+ mice immunized with rMOG synthesize MOG-specific antibodies of the IgG1 and IgG2 
isotypes (Litzenburger et al., 1998), both mechanisms (ADCC and CDC) may be operative in 
the animal model developed in this work. In addition, antibody-dependent cellular 
phagocytosis (ADCP) could also play a role. In ADCP, accessory cells with phagocytic function 
like macrophages and neutrophils, phagocytose antibody-coated bacteria through 
engagement of their Fc receptors (Janeway CA Jr, 2001). In this regard, a study reported the 
presence of phagocytic cells containing immune complexes formed by Ig and myelin proteins 
in MS lesions and EAE brain tissue (Genain et al., 1999). Considering the high specificity of 
the anti-MOG antibodies produced in Th/+ mice (Litzenburger et al., 1998) as well as the 
important role of monocytes in EAE (Yamasaki et al., 2014) and MS (Bruck et al., 1995), this 
mechanism could be operative as well in the cortical demyelination model presented here. 
 Inflammatory monocytes are required for cortical demyelination 
Since inflammatory monocytes are present in the cortical biopsies analyzed and 
constitute a major cell population infiltrating the cortex of Th/+ mice, several experiments 
were performed to elucidate their role in cortical demyelination. The experiments presented 
here suggest that inflammatory monocytes are required for the generation of cortical 
lesions. First, Th/+ CCR2-/- mice developed significantly less subpial and perivascular 
intracortical demyelinated lesions upon stereotactic cytokine injection. Additionally, the 
specific blockade of CCR2 with the antagonist RS-504393 reduced perivascular 
demyelination in CCR2-competent animals.   
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Finally, the depletion of CCR2+ inflammatory monocytes in marmoset monkeys using a 
humanized antibody against CCR2 revealed a moderate decline in subpial demyelination, 
and a significant reduction of perivascular cortical demyelinated lesions. 
Interestingly, the blockade or depletion of CCR2+ monocytes was more efficient in 
reducing perivascular than subpial cortical demyelination, suggesting that subpial 
demyelination depends less on inflammatory cells than perivascular cortical demyelination. 
As such, any interference with pathogenic cell populations impairs perivascular cortical 
demyelination measurably while subpial demyelination remains unaffected. 
 Spinal cord pathology is not modulated by CCR2 deficiency or inhibition in mice and 
marmosets 
Recently it has been demonstrated that CCR2+ monocyte-derived macrophages initiate 
spinal cord demyelination at EAE onset, often at the nodes of Ranvier (Yamasaki et al., 
2014). However, PMNs, which have been accused of taking over CCR2+ monocyte functions 
in the absence of CCR2, did not efficiently replace CCR2+ monocytes with respect to 
inflammatory demyelination (Yamasaki et al., 2014). Interestingly, spinal cord demyelination 
was comparable between Th/+ CCR2-/-and Th/+ CCR2+/+ mice, and depletion of CCR2+ 
monocytes did not significantly reduce spinal cord demyelination in marmosets immunized 
with MOG1-125. Both models differ from Yamasaka et al. by the presence of demyelinating 
serum antibodies, which might get sufficient access to the spinal cord by a T cell and PMN 
induced breakage of the spinal cord BBB. 
 Neutrophils are not instrumental for cortical demyelination 
Granulocytes contribute to astrocyte loss in anti-aquaporin-4 (AQP4) antibody-
mediated animal models of neuromyelitis optica (NMO) (Saadoun et al., 2012) and to ADCC 
in tumor models (Stockmeyer et al., 2003, Challacombe et al., 2006). In EAE, evidence has 
been provided that neutrophils constitute a significant proportion of the circulating and CNS-
infiltrating cells during the pre-clinical phase of the disease indicative of their involvement in 
the early stage of BBB breakdown (Mantovani et al., 2011, Christy et al., 2013, Aube et al., 
2014, Rumble et al., 2015). While many neutrophils can be detected in early stages of spinal 
cord EAE, a remarkable resistance of the brain to neutrophil entry has been documented in 
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acute inflammation (Andersson et al., 1992b, a, Enzmann et al., 2013). PMNs are not 
generally part of the inflammatory infiltrates of early MS lesions. However, plasma levels of 
neutrophil-related factors like CXCL5 were upregulated in RRMS patients during acute lesion 
formation and the additional expression of CXCL1 and neutrophil elastase correlated with 
clinical disability in these patients (Rumble et al., 2015). 
In the present study, the contribution of granulocytes to cortical demyelination was 
investigated by depleting neutrophils in Th/+ mice using the anti-Ly6G antibody 1A8. FACS 
analysis performed 24 hours after stereotactic intracerebral injection revealed an efficient 
depletion of circulating neutrophils in the blood and in the cerebral cortex of Th/+ mice 
treated with the anti-Ly6G antibody. However, the extent of cortical demyelination did not 
differ between depleted or non-depleted Th/+ mice, arguing against a relevant contribution 
of granulocytes to cortical demyelination in our model. 
 Natural killer cells contribute to perivascular cortical demyelination 
It is widely accepted that NK cells have two main effector functions: the direct killing of 
target cells (cytotoxicity) and the secretion of cytokines and chemokines. For a long time, NK 
cells were viewed only as “killers” but increasing attention has been given to their 
immunoregulatory function shaping adaptive immune responses (Fu et al., 2014). In EAE, NK 
cell-depletion has resulted in either an increased disease severity, related to an absence of 
NK cell-mediated killing of encephalitogenic T cells (Zhang et al., 1997, Xu et al., 2005), or an 
improvement in the clinical course of EAE (Winkler-Pickett et al., 2008). In addition, the 
expansion of CD56+ NK cells in a human-mouse chimera model of EAE improved the clinical 
disease and reduced the amount of Th17 cells in the CNS (Hao et al., 2011). 
In the present model, the depletion of NK cells in Th/+ mice resulted in a significant 
reduction of perivascular but not subpial demyelinated lesions, consistent with a 
predominant perivascular localization of NK cells in the inflamed cortex of mice and in MS 
biopsies. Furthermore, it was demonstrated that the contribution of NK cells to perivascular 
demyelination depends on a pathogenic antibody response, since perivascular demyelinated 
lesions were not observed in C57BL/6J or 2D2 mice (which also have NK cells), and on the 
IgG subclass of the antibody present.   
DISCUSSION 
 
91 
 
Additionally, NK cells contributed to perivascular cortical demyelination only in the 
presence of encephalitogenic T cells, since healthy Rag1-/- mice injected with the Z2 antibody 
did not develop perivascular intracortical lesions. 
These findings suggest that ADCC is the mechanism by which NK cells participate in 
perivascular cortical demyelination and that the recruitment of NK cells to the cortex is 
dependent on encephalitogenic T cells. In this regard, it has been shown that activated 
CD4+T cells boost NK cell activation via IL-2 secretion (Horowitz et al., 2010). 
Furthermore, NK cells can be recruited to the CNS by the secretion of chemokines, e.g. 
CX3CL1 (produced by neurons), and CCL2 and CXCL10 produced by microglia, astrocytes and 
infiltrating inflammatory cells (Shi et al., 2011). 
Evidence of NK cell-mediated ADCC has been provided in animal models of NMO 
involving the pathogenic antibody AQP4 (Ratelade et al., 2012). Further studies reported 
that NK cells could kill oligodendrocytes in vitro independently of pathogenic antibodies, 
using, among others, the activating receptor NKG2D (Morse et al., 2001, Saikali et al., 2007). 
In humans, NK cells are commonly divided into two functional subsets based on the 
cell-surface density of CD56 and CD16: CD56dim CD16+ NK cells (cytotoxic functions) and 
CD56bright CD16- NK cells (immunoregulatory functions) (Cooper et al., 2001). In MS, RRMS 
patients were shown to harbor reduced numbers of IFNγ-producing CD56bright NK cells in the 
blood (Lunemann et al., 2011), while PPMS and SPMS patients exhibited high percentages of 
circulating CD56dim NK cells with increased cytotoxic properties (Plantone et al., 2013). 
Interestingly, NK cells can exert regulatory functions in an inflammatory context by being 
cytotoxic against T cells (Bielekova et al., 2004, Bielekova et al., 2006, Hu et al., 2009, 
Bielekova et al., 2011). This hypothesis is supported further by studies in RRMS that 
associate periods of reduced NK cell killing activity with susceptibility to the development of 
clinical attacks and active lesions on MRI (Kastrukoff et al., 2003). 
Taken together, in our model, NK cells, in cooperation with an encephalitogenic T cell 
response, contribute to perivascular cortical demyelination in the presence of a pathogenic 
antibody response, which includes potent Ig isotypes for ADCC. 
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 Complement - dependent cytotoxicity contributes to subpial demyelination 
The relevance of the complement system in EAE models remains controversial. Nataf 
and colleagues reported a reduction in EAE severity in mice deficient for C3 (Nataf et al., 
2000) while another group, using a higher dose of MOG, reported similar EAE severity in 
knockout and control mice (Calida et al., 2001). Moreover, the expression of the 
complement inhibitor sCrry prevented EAE (Davoust et al., 1999), and a complement-
mediated exacerbation of the disease could be induced by transferring the pathogenic 8-
18C5 antibody into FcRγ-deficient mice, but not in C1q-deficient animals (Urich et al., 2006). 
In the present study, blocking the formation of the MAC using a C5 convertase blocking 
antibody, BB5.1, significantly reduced the extent of subpial demyelination, although 
perivascular demyelination was not decreased. Given that murine and human NK cells locate 
specifically around intracortical vessels, this may indicate that in the absence of CDC, ADCC 
can still induce substantial perivascular cortical demyelination. However, considering that 
the intracortically injected BB5.1 antibody is much larger in size than the injected cytokines, 
the BB5.1 antibody may diffuse less well in the tissue and thus, the contribution of the 
complement system to perivascular demyelination might be underestimated under these 
experimental conditions. 
It was surprising that cortical demyelination was not increased in Th/+ CD59a-/- mice. 
CD59, is an important regulator of complement activation and represents the only 
membrane bound inhibitor of C5b-9 formation (Nangaku, 2003). CD59 deficiency, in 
combination with a lack of the decay accelerating factor (DAF), a membrane bound 
complement inhibitor at the C3/C5 convertase step on erythrocytes, results in paroxysmal 
nocturnal hemoglobinuria (PNH) in humans (Risitano, 2012). 
In mice, CD59 deficiency causes spontaneous intravascular hemolysis and 
hemoglobinuria (Holt et al., 2001). However, experiments in mice and rats where CD59 
expression has been blocked, suggested that any interpretation of the results could be 
confounded by the presence of the protein Crry, an inhibitor of early complement activation. 
Crry is the rodent analogue of the human DAF and membrane cofactor protein (MCP), both 
regulators of the complement cascade. Several studies in models of glomerular endothelial 
injury in rats (Nangaku et al., 1998) or nephropathy models (Cunningham et al., 2001) 
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suggest an essential role for CD59 only when upstream inhibitors of the complement 
cascade are exhausted by excessive activation or loss of inhibitory functions. Thus, the 
presence of Crry, mediating upstream regulation of the complement cascade might explain 
the results obtained in Th/+ CD59a-/- mice in the present work. 
 Encephalitogenic T cells are dispensable for subpial but not for perivascular cortical 
demyelination 
Myelin reactive T cells are instrumental for EAE induction (Furtado et al., 2008, 
O'Connor et al., 2008). The present study demonstrates that encephalitogenic T cells are 
dispensable for subpial but not for perivascular demyelination, since Rag1-/- healthy mice i.v. 
injected with the pathogenic antibody 8-18C5 and stereotactically injected with the pro-
inflammatory cytokine mixture, developed subpial but not perivascular lesions. 
Furthermore, it was demonstrated that only myelin-specific, activated T cells were able to 
trigger the formation of perivascular cortical demyelination. 
The conclusion that encephalitogenic T cells are required for perivascular but not for 
subpial cortical demyelination was supported by experiments assessing intracortical 
extravasation of FITC-albumin in healthy versus diseased Th/+ mice stereotactically injected 
with pro-inflammatory cytokines. Extravasation of FITC-albumin from intracortical vessels 
was significantly more pronounced in diseased animals and first observable 24 h after 
injection. In contrast, subpial albumin-FITC extravasation was already observed at 6 h, 
becoming substantial in both experimental paradigms 24 h after lesion induction, indicating 
that intracortically injected cytokines are sufficient to open meningeal or subpial cortical 
vessels effectively. In contrast, intracortical vessels might require a stronger stimulus, like 
the interaction with encephalitogenic T cells or other inflammatory cells to become 
permeable to FITC-albumin. 
Several experimental models and studies in MS tissue support the role of inflammatory 
cytokines for demyelination and thus highlight the significance of the results obtained here. 
For example, TNFα, lL-1β and IL-17A have been reported to increase BBB permeability and 
activate parenchymal vessels (Brown and Sawchenko, 2007, Steinman, 2013). Moreover, the 
stereotactic injection of IFNγ and TNFα in MOG-immunized rats induced meningeal and 
DISCUSSION 
 
94 
 
intracortical inflammation accompanied by extensive subpial and intracortical demyelination 
(Merkler et al., 2006b, Gardner et al., 2013). Also, high levels of these two cytokines have 
been detected in the CSF of MS patients during acute relapses (Maimone et al., 1991), and it 
has been proposed that the diffusion of pro-inflammatory cytokines from inflamed meninges 
could support the cortical pathology observed in the upper demyelinated layers of the brain 
(Magliozzi et al., 2010). In line, recent findings report IFNγ and TNFα expression in T cells and 
monocytes/macrophages respectively, accumulated in the inflamed meninges of SPMS 
brains (Gardner et al., 2013). 
Reiteratively, the results obtained in this study denote the existence of distinct barrier 
properties within the cortical vasculature that might differentially influence tissue 
vulnerability to demyelination. In this respect, slight differences between meningeal and 
parenchymal vessels have been reported. Meningeal vessels lack astrocytic ensheathment 
(Allt and Lawrenson, 1997), which may make them more permeable to immune cells and 
soluble factors, whereas parenchymal microvessels lack the expression of P-selectin 
(Barkalow et al., 1996, Yong et al., 1997, Kivisakk et al., 2003). It has been shown that P-
selectin expression in meningeal vessels and in the choroid plexus stromal vessels promotes 
lymphocyte trafficking into the SAS and the CSF respectively (Carrithers et al., 2000, Kivisakk 
et al., 2003, Ransohoff and Engelhardt, 2012). In this regard, imaging studies in EAE 
confirmed that the SAS is the first place where encephalitogenic T cells are reactivated by 
APC, resulting in proliferation and parenchymal infiltration. Subsequently, the parenchymal 
vasculature becomes activated as part of a two-step process orchestrated by immune cells 
to invade the CNS (Lassmann and Wisniewski, 1978, Bartholomaus et al., 2009, Kivisakk et 
al., 2009, Reboldi et al., 2009), which might also explain the delayed perivascular 
extravasation of FITC-albumin observed between the 6 h and 24 h time points. 
The blockade of VLA-4 with the antibody PS/2 does not modulate cortical demyelination in 
Th/+ mice 
The specific α4-integrin chain (CD49d) and the common β1-integrin chain (CD29) form 
the integrin VLA-4 (Schwab et al., 2015). Once VLA-4 is activated by chemokines (Campbell et 
al., 1998), it binds to VCAM-1 on endothelial cells of the BBB and mediates firm adhesion of 
immune cells, as a pre-requisite for transmigration (Engelhardt and Ransohoff, 2012).   
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The rationale behind blocking the expression of VLA-4 in stereotactically injected Th/+ 
mice using the PS/2 antibody was based on previous studies where blocking α4-integrin has 
been shown to be protective in both EAE and MS (Yednock et al., 1992, Engelhardt et al., 
1998, Polman et al., 2006, Stuve et al., 2006, Hausler et al., 2015). Indeed, the blockade of 
VLA-4 with the monoclonal antibody Natalizumab has become the most effective therapy for 
RRMS patients (Schwab et al., 2015). In the present study, treatment with the Natalizumab 
mouse analogue PS/2 did not protect Th/+ mice against subpial cortical demyelination, in 
line with the notion that subpial demyelination is less dependent on the infiltration of 
inflammatory cells. 
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5 SUMMARY AND CONCLUSIONS 
Inflammatory demyelination is the histopathological hallmark of MS and does not only 
affect the white matter but also the cortex. Imaging and histopathological studies suggest 
that cortical pathology is a correlate of cognitive dysfunction and disease progression, and 
driven by an inflammatory process in early stages of the disease. Cortical demyelinated 
lesions have been classified into subpial, perivascular (intracortical) and leukocortical lesions 
according to lesion localization. Subpial demyelinated plaques are by far, the most frequent 
and extensive cortical lesion type. First, the cortical immune cell infiltration was 
characterized in more detail in a cohort of eight MS biopsies. T cells, CCR2+ monocytes and 
microglia activation were observed in cortical demyelinated areas. Interestingly, NK cells 
were present as well, mainly localized around inflamed cortical vessels. 
To elucidate the contribution of immune cell subpopulations to cortical demyelination, 
a novel cortical demyelination model in the mouse was established. The model combined 
the heavy chain knock-in mouse for 8-18C5, a well-known demyelinating antibody, (Th/+ 
mouse) with a stereotactic targeting approach to induce cortical demyelination. Th/+ mice 
developed MS-like subpial and perivascular cortical demyelinated lesions in response to 
intracortical cytokine injections also in the non-injected hemisphere, which translated 
clinically into a transient deficit to adapt to complex wheel running. Time course 
experiments demonstrated that cortical inflammation resolved rapidly and that the 
demyelinated lesions remyelinated efficiently. Axonal damage, as evidenced by APP+ axons 
was present around demyelinated cortical vessels but neuronal numbers were not reduced. 
CCR2+ monocytes were found to be instrumental for cortical demyelination, since 
Th/+ CCR2-/- had significantly less subpial and perivascular cortical demyelination than 
Th/+ CCR2+/+ mice. In order to translate our results into a preclinical treatment approach, we 
evaluated a novel humanized antibody against CCR2, which efficiently depletes CCR2+ 
monocytes in the marmoset EAE model. A moderate reduction of subpial and a significant 
reduction of perivascular cortical demyelination in response to CCR2+ monocyte depletion 
were observed, further substantiating their importance for cortical demyelination. Depleting 
marmosets of CCR2+ monocytes was well tolerated, and this targeted therapy might be a 
future treatment option for MS. 
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NK cells were found to augment perivascular but not subpial cortical demyelination, 
which was in line with a preferential perivascular localization of NK cells in human cortical 
lesions as well as in the mouse demyelinated cortex. The contribution of NK cells to 
perivascular cortical demyelination depended on encephalitogenic T cells and the IgG2a 
isotype of the demyelinating antibody. This suggests that T cells are required for the 
recruitment of NK cells to the inflamed cortex and that NK cells contribute to cortical 
demyelination through ADCC. 
Next, the contribution of adaptive immune cells for cortical demyelination was 
dissected. Antigen presenting functions of B cells were neither required for subpial nor for 
perivascular cortical demyelination in the presence of a demyelinating antibody. In contrast, 
activated and myelin-specific T cells were absolutely required for perivascular cortical 
demyelination but also dispensable for subpial cortical demyelination, suggesting that 
subpial cortical demyelination is largely independent of adaptive immunity. In this line, 
blockade of α4-integrin with PS/2, the mouse analogue of Natalizumab, did not reduce 
subpial demyelination. However, subpial demyelination was reduced in the presence of an 
antibody blocking the generation of the membrane attack complex, highlighting the classical 
complement pathway as an effector mechanism for subpial demyelination. 
In order to better understand why subpial demyelination is generated much easier 
than perivascular cortical demyelination, FITC-albumin was injected in healthy versus 
diseased Th/+ mice. A comparable extent of subpial extravasation of FITC-albumin was 
observed in both healthy and diseased Th/+ mice, in response to intracortical cytokine 
injections, while perivascular FITC-albumin extravasation was restricted to diseased animals. 
This suggests that meningeal and intracortical vessels differ with respect to their barrier 
functions. 
In summary, we have developed a novel animal model for cortical demyelination in the 
mouse, which has proven to be predictive for a novel targeted therapy evaluated in 
marmosets. It also demonstrates the exquisite vulnerability of the subpial cortex for 
demyelination and offers a rational explanation why treatments targeting the adaptive 
immune response might fail in preventing subpial demyelination, the most extensive cortical 
lesion type seen in progressive MS. 
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